 
CicloMed LLC  
 
CLINICAL STUDY PROTOCOL  
 
 
Study Title:  A Phase 1, First-in-Human, Safety, Dose Tolerance, 
Pharmacokinetics , and Pharmacodynamics  Study  of CPX -POM 
in Patients with Advanced Solid Tumors  
  
Sponsor:  CicloMed LLC  
411 Nichols Rd.  
Suite 217  
Kansas City, MO 64112  
  
IND No.:  
clinicalt rials.gov Identifier : 13254 5 
[STUDY_ID_REMOVED]  
  
Indication:  Advanced Solid Tumors  
  
Protocol ID:  CPX -POM -001 
  
  
Protocol Version s/Date s: Original Protocol Version 1.0 / 15 August 2017  
Amendment 1, Version 2.0 / 1 9 September 2017  
Amendment 2, Version 3.0 / 03 November  2017  
Amendment 3, Version 4.0 / 04 January 2018  
Amendment 4, Version 5.0 / 06 August  2018  
 
CONFIDENTIALITY STATEMENT  
The information contained in this document, particularly unpublished data, is the property or under control 
of CicloMed LLC , and is provided to you in confidence as an investigator, potential investigator, or 
consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent 
Ethics Committee. The information is only to be used by you in connection with authorized clinical studies 
of the investigational drug described in the protocol. You will not disclose any of the infor mation to others 
without written authorization from CicloMed LLC , except to the extent necessary to obtain informed 
consent from those persons to whom the drug may be administered.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  2 SPONSOR  SIGNATURE PAGE  
 
CicloMed LLC  
411 Nichols Rd.  
Suite 217  
Kansas City, MO 64112  
 
A Phase 1, First -in-Human, Safety, Dose Tolerance, Pharmacokinetics, and 
Pharmacodynamics Study of CPX -POM in Patients with Advanced Solid Tumors  
Amendment 4, Version 5.0, 06 August  2018 . 
This protocol has been approved by CicloMed LLC .  The following signature s document this 
approval.  
 
 
 
   
William McCulloch, MB, FRCP, FFPM  
Medical Consultant  
CicloMed LLC   (Date)  
 
 
 
   
 
  
Scott J Weir, PharmD, PhD  
Chief Scientific Officer [Acting]  
CicloMed LLC   (Date)  
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  3 INVESTIGATOR  PROTOCOL AGREEMENT  
A Phase 1, First -in-Human, Safety, Dose Tolerance, Pharmacokinetics, and 
Pharmacodynamics Study of CPX -POM in Patients with Advanced Solid Tumors  
Amendment 4, Version 5.0, 06 August  2018  
 
By my signature, I  
• Confirm that my staff and I have carefully read and understand this protocol and the 
Investigator’s Brochure (IB) and are thoroughly familiar with the appropriate use of 
the investigational drug described herein.   
• Agree to comply with the conduct and terms of the study specified herein and with 
any other study procedures provided by the Sponsor, CicloMed LLC .   
• Agree to comply with US Food and Drug Administration (FDA) regulations, the 
International Conference on Harmonization (ICH) Good Clinical Practices ( GCP ) 
guidelines, the Declaration of Helsinki, and all applicable rules, regulations, and 
federal, state, and local laws relating to the conduct of clinical studies and the 
protection of human subjects.  
• Agree not to implement changes to the protocol without agreement from the Sponsor 
and prior written approval (where required) from the Institutional Review Board 
(IRB), except when necessary to eliminate an immediate hazard to the subjects.  
• Agree to onsite monitoring of the case report  forms (CRFs) and source documents by 
the Sponsor or designee and to audit by the Sponsor or designee and appropriate 
regulatory authorities, including, but not limited to, the FDA and IRB inspectors.  
• Agree to supervise the conduct of the study and maintai n responsibility for training 
and supervising all personnel who have been delegated responsibilities under my 
leadership.  The protocol and other important study materials will be available to 
study staff throughout the conduct of the study.  
   
Investigator's Signature   Date  
   
Print Name  
 
 
   
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  4 TABLE OF CONTENTS  
 
1. PROTOCOL SUMMARY  ................................ ................................ ................................ ........................  7 
1.1. Synopsis  ................................ ................................ ................................ ................................ ....... 7 
1.2. Study Diagram  ................................ ................................ ................................ ............................  11 
1.3. Schedule of Assessments  ................................ ................................ ................................ ............  13 
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS  ................................ ..........................  18 
2. INTRODUCTION ................................ ................................ ................................ ................................ ... 21 
3. OBJECTIVES  ................................ ................................ ................................ ................................ .........  23 
4. STUDY DESIGN  ................................ ................................ ................................ ................................ .... 24 
4.1. Overall Design  ................................ ................................ ................................ ............................  24 
4.2. Planned Doses for Dose Escalation  ................................ ................................ .............................  26 
4.3. Rationale for Study Design  ................................ ................................ ................................ .........  27 
4.4. Dose Selection  ................................ ................................ ................................ ............................  28 
4.5. End of Study Definition  ................................ ................................ ................................ ..............  28 
5. STUDY POPULATION  ................................ ................................ ................................ ..........................  29 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........................  29 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......................  30 
5.3. Meals and Dietary Considerations  ................................ ................................ ...............................  32 
5.4. Screen Failures  ................................ ................................ ................................ ...........................  32 
6. TREATMENTS  ................................ ................................ ................................ ................................ ...... 33 
6.1. Investigational Product  ................................ ................................ ................................ ...............  33 
6.1.1.  Description of Investigational Product  ................................ ................................ ....... 33 
6.1.2.  Packaging and Labeling  ................................ ................................ .............................  33 
6.1.3.  Storage and Handling  ................................ ................................ ................................  33 
6.1.4.  Dosage and Administration ................................ ................................ ........................  33 
6.1.5.  Dose Modifications  ................................ ................................ ................................ ... 34 
6.1.6.  Compliance  ................................ ................................ ................................ ...............  34 
6.1.7.  Accountability  ................................ ................................ ................................ ...........  34 
6.2. Prior and Concomitant Medications  ................................ ................................ ............................  35 
7. DISCONTINUATION OF STUDY INTERVENTION AND PATIENT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ................................  36 
7.1. Discontinuation of Study Treatment  ................................ ................................ ............................  36 
7.2. Patient Discontinuation/Withdrawal from the Study  ................................ ................................ .... 36 
7.3. Lost to Follow Up  ................................ ................................ ................................ .......................  36 
8. STUDY ASSESSMENTS  ................................ ................................ ................................ .......................  38 
8.1. Cancer Evaluation  ................................ ................................ ................................ .......................  38 
8.2. Safety Assessments  ................................ ................................ ................................ .....................  38 
8.2.1.  Adverse Events and Serious Adverse Events  ................................ .............................  38 
8.2.2.  Pregnancy  ................................ ................................ ................................ ..................  43 
8.2.3.  Other Safety and Screening Assessments  ................................ ................................ ... 44 
8.3. Pharmacokinetic Assessments  ................................ ................................ ................................ ..... 48 
8.4. Pharmacodynamic Assessme nts ................................ ................................ ................................ .. 48 
9. STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..... 49 
9.1. Number of Patients  ................................ ................................ ................................ .....................  49 
9.2. Analysis Sets  ................................ ................................ ................................ ..............................  49 
9.2.1.  Safety  ................................ ................................ ................................ ........................  49 
9.2.2.  Pharmacokinetics ................................ ................................ ................................ ....... 49 
9.3. Data Handling Conventions  ................................ ................................ ................................ ........  49 
9.4. Demographic Data and Baseline Characteristics  ................................ ................................ .........  49 
9.5. Safety Analysis  ................................ ................................ ................................ ...........................  49 
9.5.1.  Determination of Maximum Tolerated Dose  ................................ ..............................  50 
9.5.2.  Extent of Exposure  ................................ ................................ ................................ .... 50 
9.5.3.  Adverse Events  ................................ ................................ ................................ ..........  50 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  5 9.5.4.  Laboratory Evaluations  ................................ ................................ ..............................  50 
9.5.5.  Other Safety Evaluations  ................................ ................................ ...........................  51 
9.6. Pharmacokinetic Analysis  ................................ ................................ ................................ ...........  51 
9.6.1.  Pharmacokinetics in Plasma  ................................ ................................ ......................  51 
9.6.2.  Pharmacokinetics in Urine  ................................ ................................ .........................  52 
9.6.3.  Covariates and Pharmacok inetics  ................................ ................................ ...............  52 
9.7. Pharmacodynamic Analyses  ................................ ................................ ................................ ....... 52 
9.8. Interim Analyses  ................................ ................................ ................................ .........................  53 
10. REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS  ................................ .. 54 
10.1.  Regulatory and Ethical Considerations  ................................ ................................ ........................  54 
10.1.1.  Institutional Review Board/Ethics Committee  ................................ ...........................  54 
10.1.2.  Ethical Conduct of the Study  ................................ ................................ .....................  54 
10.1.3.  Informed Consent  ................................ ................................ ................................ ...... 55 
10.1.4.  Confidentiality ................................ ................................ ................................ ...........  55 
10.2.  Study Oversight  ................................ ................................ ................................ ..........................  56 
10.2.1.  Data Quality Assurance  ................................ ................................ .............................  56 
10.2.2.  Source Documents  ................................ ................................ ................................ ..... 56 
10.2.3.  Study and Site Closure  ................................ ................................ ..............................  56 
10.2.4.  Reporting of Results and Publications ................................ ................................ ........  57 
10.2.5.  Study Files and Retention of Records  ................................ ................................ ........  58 
10.2.6.  Case Report Forms  ................................ ................................ ................................ .... 59 
10.2.7.  Inspections  ................................ ................................ ................................ ................  59 
10.2.8.  Protocol Compliance  ................................ ................................ ................................ . 59 
10.2.9.  Study Discontinuation  ................................ ................................ ...............................  59 
11. REFERENCES  ................................ ................................ ................................ ................................ ....... 60 
12. APPENDIX  ................................ ................................ ................................ ................................ .............  62 
 
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  6 LIST OF IN -TEXT TABLES  
 
Table  1. Schedule of Assessments  ................................ ................................ ...........................  14 
Table 2.  Dose Escalation Procedures  ................................ ................................ .......................  25 
Table  3. Example Doses for Accelerated Titration Cohorts  ................................ ......................  27 
Table  4. Example Doses for Standard Dose Escalation Cohorts  ................................ ...............  27 
Table  5. Eastern Cooperative Performance Status  ................................ ................................ .... 45 
Table  6. Listing of Required Screening and Safety Laboratory Parameters  ..............................  47 
 
 
LIST OF IN -TEXT FIGURES  
 
Figure  1. Study Design  ................................ ................................ ................................ .............  12 
 
 
LIST OF APPENDICES  
Appendix 1.  RECIST Criteria Guidance  ................................ ................................ ........................  62 
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  7 1. PROTOCOL SUMMARY  
1.1. Synopsis  
CicloMed LLC  
411 Nichols Rd.  
Suite 217  
Kansas City, MO 64112  
 
Study Title:  A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics , and 
Pharmacodynamics Study of CPX -POM in Patients with Advanced Solid 
Tumors  
IND Number:  132545  
Study Centers 
Planned:  Approximately 6 centers in the United States  
Objectives:  The primary objective of this study is  as follows : 
• To evaluate the dose limiting toxicities (DLTs) and maximum tolerated 
dose (MTD) of ciclopirox phosphoryloxymethyl ester (CPX -POM ) 
administered intravenously ( IV) and establish the CPX -POM dose 
recommended for further investigation . 
The secondary objective s of this study are  as follows :  
• To characterize the plasma and urine pharmacokinetics (PK) of CPX -POM 
and its metabolites following single and multiple dose administration;  
• To identify preliminary anti -tumor activity of CPX -POM ;  
• To determine urine β -glucuronidase activity in patients participating in the 
trial. 
The exploratory objective s of this study are as follows : 
• To characterize the pharmacologic effects of CPX -POM on circulating 
biomarkers of Wnt and Notch cell signaling pathways ; 
• To explore pharmacodynamic  (PD)  relationships between changes in 
circulating biomarkers and drug and/or metabolites exposure and other 
outcomes.  
Study Design:  This is a first -in-human, Phase 1, multicenter, open label, dose escalati on study 
to evaluate the DLT s and MTD and to determine the recommended Phase 2 
dose (RP2D) of CPX -POM administered IV in patients with any histologically - 
or cytologically -confirmed s olid tumor type.  Secondary objectives include 
characterization of the safety and PK profile of CPX -POM and identification of 
preliminary anti -tumor activity in this patient population.  Biomarkers  and their 
relationship to PK and other outcomes will be examined as an exploratory 
objective.  
The study will initially employ an accelerated escalation  design, with a single 
patient enrolled in each cohort (i.e., Single -Patient Cohorts ).  The initial patient 
cohort will receive CPX -POM at a starting dose of 30 mg/m2.  Doses will be 
escalated in 100 % increments (i.e., doubling), until  a ≥Grade 2 toxicity (with 
the exception of alopecia), as determined according to the United States (US) 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  8 National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE), version 4.03, is encountere d, at which point that cohort and 
all subsequent cohorts will follow a classical “3 + 3” dose  escalation design 
(i.e., Standard Dose Escalation Cohorts).   
After each cohort is completed, a Safety Review Committee ( SRC ) comprised 
of the CRO Medical  Monitor , Principal Investigator (s), and Sponsor 
representatives will meet to discuss the data and decide upon the next dose 
escalation.   Doses in the standard cohorts will be escalated in 25 to 50% 
increments, based on SRC decision, until the MTD is reached.   In addition, 
after completion of Cycle 1 for the first 4 to 6 patients, the SRC will review 
safety, PK, and PD data to determine if any changes to the dosing schedule are 
indicated.  
Intrapatient dose escalation will not be allowed in any patient  at any time.  
Each patient in a dose cohort must have received at least 8 0% of their 
CPX -POM doses, unless due to toxicity, during Cycle 1 with follow -up safety 
evaluations through Day 22 (or Cycle 2, Day 1 , if continuing in the study)  to be 
eligible for t he assessment of DLT.   
Patients may  continue to receive cycles of CPX -POM  until progression of 
disease , intolerable toxicity occurs , or another withdrawal criterion applies . 
Approximately 24 patients will be enrolled in the Single -Patient and Standard 
Dose Escalation Cohorts to establish the MTD.  In addition to these  estimated  
24 patients, E xpansion Cohort(s) may be enrolled after the MTD is reached to 
either explore different dosing schedules , increase the experience with a 
particular tumor type (e.g., muscle invasive bladder cancer [ MIBC ]), or to 
examine the safety and anti -tumor activity of CPX -POM in combination with  
certain other anticancer agents .   
Dose escalation procedures will be condu cted as follows:    
 Accelerated Titration ( Single -Patient Cohorts ; n=1 each)  
 No ≥Grade 2 adverse 
events ( AEs) • Continue evaluation of single -patient dose 
cohorts.  
• Escalate by 100% to next dose level.  
 At least 1 ≥Grade 2 
AE not meeting the 
definition of DLT  • Expand current and subsequent cohorts to at least 
3 patients (see Standard Dose Escalation Scheme 
below).  
 1 DLT  • Expand current cohort up to 6 patients or until 
2 DLTs are encountered (Standard Dose 
Escalation Scheme below).  
 Standard Dose Escalation (Standard Cohorts; n=3  to 6 each)  
 No DLT  • Escalate by 25 −50% to next dose level.  
 1 DLT in ≤3 patients  • Expand cohort up to 6 patients.  
 1 DLT in 6 patients  • Escalate by 25 −50% to next dose level.  
 > 1 DLT in ≤ 6 
patients  • MTD reached; stop dose escalation.   
• Possibly explore intermediate doses for the RP2D.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  9  A Dose -Limiting Toxicity will be defined as any of the following  if deemed 
related to study drug : 
• Grade 4 thrombocytopenia of any duration  
• Grade 3 thrombocytopenia with significant hemorrhage of any duration  
• Grade 4 absolute neutrophil count ( ANC ) >5 days  
• Febrile neutropenia  
• Grade ≥3 non -hematologic toxicity of any duration, except:   
o Grade 3 nausea , vomiting, or diarrhea and Grade 4 vomiting or diarrhea 
in the absence of maximal medi cal therapy that resolves in 72  hours  
o Grade 3 fatigue lasting <5 days  
o Grade 3 hypertension  that can be controlled with medical therapy  
o An increase of indirect (unconjugated) bilirubin indicative of 
M. Meulengracht/Gilbert’s syndrome  
o Serum lipase and/or serum amylase CTCAE Grade 3 ≤7 consecutive 
days without clinical signs or symptoms of pancrea titis  
• Delay in study drug due to toxicity for >2 weeks   
• Alanine aminotransferase ( ALT )/aspartate aminotransferase ( AST ) 
>3xULN with bilirubin >2x  the upper limit of normal ( ULN ) without 
another explanation (e.g., cholestasis)  
Any patient who is unable t o receive 80% of the expected dose of CPX -POM 
(i.e., patients who are unable to receive at least 4 of the 5 scheduled doses) 
because of AEs will be considered to have a DLT.  
Number of 
Patient s 
Planned:  Approximately 24 patients  will be enrolled in dose escalation cohorts to 
establish the MTD.   In addition to these estimated  24 patients, Expansion 
Cohort(s) may also be enrolled after the MTD is reached.  
Target 
Population:  Patients with  any histologically - or cytologically -confirmed s olid tumor type  
that is refractory to standard therapy .   Patients should only be included if no 
therapy exists or if they have received all standard therapies that would be 
potentially curative or might provide significant benefit .   
Duration of 
Study : Patients who receive one treatment cycle will be in this study for up to 
approximately  8 weeks:  up to a 28-day Screening period, a 21-day Treatment 
cycle , and a Follow -up period  out to 28  ± 5-days after the last dose (i.e., 
approximately Day 33) .  After the first treatment cycle, patients may  continue 
to receive cycles of CPX -POM  until progression of disease , intolerable toxicity 
occurs , or another withdrawal criterion applies .   
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  10 Diagnosis and 
Main Eligibility 
Criteria:  Patients eligible for enrollment in this study will be adults with any 
histologically - or cytologically -confirmed metastatic or advanced -stage solid 
tumor  that is refractory to standard therapy .  Patients should only be included if 
no therapy exists or if they have received all standard therapies  that would be 
potentially curative or might provide significant benefit .  Patients must have a 
life expectancy ≥3 months, an  Eastern Cooperative Oncology Group  (ECOG ) 
Performance Status 0 or 1 , no significant ische mic heart disease , adequate 
hepatic function, and a baseline  glomerular filtration rate ( GFR ) 
>50 mL/min/1.73m2.  Females must not be pregnant and, if of childbearing 
potential, must use an effective method of contraception to avoid pregnancy 
during and fo r 3 months after participation in the trial.   
Patients who have any risk factor for torsade de pointes or any uncontrolled or 
severe intercurrent medical condition, or who have had major surgery or prior 
systemic chemotherapy  or radiation therapy within th e previous 4 weeks are 
excluded . 
Test Product, 
Dose, and Mode 
of 
Administration:  Escalating doses of CPX -POM will be administered by 10-minute IV infusion 
once daily on Days  1-5 of each 21 -day cycle .   
After completion of Cycle 1 for the first 4 to 6 patients, the SRC will review 
safety, PK, and PD data to determine if any changes to the dosing schedule are 
indicated (e.g., adding an additional 5 days of dosing to each treatment cycle).   
Patients may  continue to receive cycles of CPX -POM  until progression of 
disease , intolerable toxicity occurs , or another withdrawal criterion applies .  
The starting dose will be 30 mg/m2.   
Reference 
Therapy, Dose, 
and Mode of 
Administration:  Not applicable.  
Criteria for 
Evaluation:  Safety : 
Safety and tolerability will be based on an assessment of AEs, physical 
examinations, vital signs, electrocardiograms ( ECGs ), clinical laboratory tests, 
ophthalmologic assessments, and concomitant medications.   
The MTD wil l be defined as the dose BELOW that dose which causes DLTs in  
≥33% of patients.  
Pharmacokinetics:  
Serial blood (plasma) samples and complete urine will be collected over 
24-hour periods starting after the first (Day 1) and fifth (Day 5) doses of 
CPX -POM  during Cycle 1 to characterize single dose and steady -state plasma 
and urine PK of CPX -POM, ciclopirox  (CPX) , and ciclopirox glucuronide  
(CPX -G).  If patients are unable or unwilling to attend the required 12 hours of 
clinic visitation required for steady -state PK sampling on Day 5 of Cycle 1, the 
steady -state PK sampling may be postponed to Day 5 of Cycle 2.  Urine β -
glucuronidase activity will be m easured prior to and after 5 days of CPX -POM 
administration  (i.e., on Days 1 and 5 of Cycle  1).   
Pharmacodynamics:  
Blood will be collected to characterize the effects of CPX -POM on circulating 
biomarkers of Wnt and Notch cell signaling pathways.  Plasma a nd peripheral 
blood mononuclear cells (PBMCs) will be isolated from blood.  Vascular 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  11 endothelial growth factor (VEGF ), interleukin (IL) -6, and IL -8 concentrations 
will be measured in plasma by enzyme -linked immunoassay (ELISA).  
Quantitative real-time poly merase chain reaction  (qRT -PCR) will be used to 
characterize gene expression of circulati ng biomarkers of Wnt and Notch 
signaling pathways in PBMCs.  
Statistical 
Methods:  Safety:  
Safety data will be presented in by -patient listings.  Categorical safety 
endpoints will be summarized by frequency of events/abnormalities for each 
dose group and overall.  Continuous safety endpoints will be summarized using 
descriptive statistics ( number  of subjects [ n], mean, standard deviation, median, 
first quartile [ Q1], third quartile [ Q3], minimum, maximum ) for each dose 
group and overall.   
Pharmacokinetics:  
Standard  PK parameters will be derived from resultant plasma and urine drug 
and metabolite concentration -time data using non -parametric methods.   PK 
parameters will be summarized using descriptive statistics.   
Pharmacodynamics : 
A logistic regression will be used to estimate the predicted toxicity probability 
at each dose level.  Relationship s between dose, drug and metabolite exposure, 
PD response , and other endpoints (i.e ., ECGs, toxicity, safety, and biomarker 
endpoints) may be  explored using descriptive statistics, and/or additional 
PK/PD modeling.  
 
This study will be conducted in accordance with the guidelines of current GCPs including 
archiving of essential documents.   
1.2. Study Diagram  
The study design is illustrated in Figure  1. 
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
CONFIDENTIAL   Page  12 Figure  1. Study Design  
 
Abbreviations:  CPX -POM = ciclopirox phosphoryloxymethyl e ster; D = day; PD = pharmacodynamic; PK = pharmacokinetic; V = visit.  
 
CPX-POM -01-001 Study Design –19 Sep 2017
Study Day: D -14 to -1Informed consent and screening eligibility assessments 
28 ±5 days 
after end of 
last cycle CPX-POM dosing, PK (pre -dose [trough] sample , Cycle 1 only), and 
safety assessments,
Safety follow -up visit
V1 Study Visit:D1
V2
CPX-POM dosing, PK (Cycle 1 only) , PD, and safety assessments
D2
V3
D 3-D4
V4–V5D22/
early 
termination
If  final  treatment cycle, patient returns for Safety and PD 
assessments on  Day 22.  If additional cycles are planned, 
patient skips this visit and restarts schedule at Day 1 (except for PK).  
D10
Cycle 1 onlyCPX-POM dosing and safety assessments
No dosing  or study visits, Days 7-9
D5
V6
CPX-POM dosing, PK (Cycle 1 only) , PD, and safety assessments
D 6
V7
Trough PK sample, (Cycle 1 only)  and safety assessments
D 7–D9
 D 11–D21
V8
No dosing  or study visits, Days  11 -21Safety assessments (Cycle 1 only)
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
CONFIDENTIAL   Page  13 1.3. Schedule of Assessments  
The schedule of assessments is shown in Table  1. 
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
CONFIDENTIAL   Page  14 Table  1. Schedule of Assessments  
Study Procedure  Screening  
Period  Treatment Period  Follow -up 
Period  5 
Study Days:  D -28 to  
D -1 D1 1 D2 D3 D4 D5 1 D6 D10 2 
(Cycle 1 
only)  D22  
(last cycle) 4 28 (±5) days  
post last  dose 
or at  early 
termination  Study Visits:  V1 V2 V3 V4 V5 V6 V7 V8 
Informed consent  X          
Inclusion/exclusion criteria  X X         
ECOG Performance Status  X         X 
Medical history  X          
HIV and hepatitis screening  6 X          
Pregnancy test  7 X X         
Cancer evaluation 8 X X         
CT or MRI  X          
MUGA or ECHO  X          
Hematology 9 X X   X   X X X 
Clinical chemistry 10 X X   X   X X X 
Thyroid panel 11 X X         
Coagulation test 12 X X         
Urinalysis 13 X X    X  X X X 
Full p hysical exam  14 X         X 
Assess for physical 
symptoms/toxicities 15  X X X X X X X X  
Ophthalmologic exam 15 X         X 
Vital signs 16 X X X X X X X X X X 
ECG 17 X X    X    X 
Start 24 - hour Holter monitor 18  X         
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
CONFIDENTIAL   Page  15 Study Procedure  Screening  
Period  Treatment Period  Follow -up 
Period  5 
Study Days:  D -28 to  
D -1 D1 1 D2 D3 D4 D5 1 D6 D10 2 
(Cycle 1 
only)  D22  
(last cycle) 4 28 (±5) days  
post last  dose 
or at  early 
termination  Study Visits:  V1 V2 V3 V4 V5 V6 V7 V8 
Adverse events  X X X X X X X X X X 
Concomitant med ications  X X X X X X X X X X 
PK blood samples 19  X X   X X    
PK urine samples 20  X X   X X    
β glucuronidase urine sample 21  X    X     
Biomarker blood sample 22  X    X   X X 
Body surface area 23  X         
CPX -POM in fusio ns 24  X X X X X     
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate 
aminotransferase; BSA = body surface area; BUN = blood urea nitrogen; CPX -=POM = ciclopirox phosphoryloxymethyl ester ; CT = computed tomography; 
D = day; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EDTA = ethylenediamine tetraacetic acid; eGFR = estimated 
glomerular filtration rate; GGT = gamma glutamyl transferase; HIV = human immunodeficiency virus; IV = intravenous; MUGA = multi -gated acquisition ; 
MRI = m agnetic resonance imaging ; PBMC = peripheral blood mononuclear cell; PD = pharmacodynamic;  PK = pharmac okinetic; PT = prothrombin time; 
RBC = red blood cell; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid stimulating hormone; V = visit; WBC = white b lood cell.   
1. On Days 1 and 5 of Cycle 1, patients will be required to stay at the clinical research unit for at least 12  hours for PK sampling and other 
assessments.  If patients are unable or unwilling to attend the required 12 hours of clinic visitation required for steady -state PK  sampling on Day 5 
of Cycle 1, the steady -state PK sampling may be postponed to Day 5 of Cycle 2.  To shorten the duration of the Cycle 1, Day 1 visit, if needed, the 
safety laboratory blood samples required for this visit may be drawn up to 3 days before Day 1.  
2. The Day 10 (Visit 8) study visit will only be required during Cycle 1.   
3. After cycle 1; visit windows can be considered on a case by case basis due to events such as holidays; Cycle 1 needs to occur  without visit 
windows . D6 can occur +2 calendar days for cycles after Cycle 1 is completed.  
4. If final treatment cycle, patient returns for assessments on Day 2 2.  If additional cycles are planned, patient skips this visit and restarts schedule at 
Day 1 (except for PK).  Patients may continue to receive cycles of CPX -POM until progression of disease, intolerable toxicity occurs, or another 
withdrawal criterion applies.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
CONFIDENTIAL   Page  16 5. The Follow -up visit will occur 28±5 days after the last dose of CPX -POM administered during the last treatment cycle.  Or, in the event that a 
patient discontinues from the study prematurely, the site will make every effort to perform the assessments listed for this s tudy visit.  
6. Hepatitis screening will include tests for  Hepatitis A,  Hepatitis B, and Hepatitis C .  
7. Pregnancy tests wi ll be required only for women of child bearing potential  at Screening and before dosing on Day 1 of each treatment cycle .  Urine 
or serum pregnancy tests are acceptable .  
8. Cancer evaluation will include determination of staging and metastases for screening purposes  (see Section 8.1).  Disease response assessments will 
be performed for patients with measurable  disease within 28 days prior to the first dose of CPX -POM and repeated at the end  of every second cycle 
(i.e., at approximately 6 -week intervals) .  During the Dose -Escalation Phase  of the study, Screening cancer evaluations may be performed up to 28 
days before  Cycle 1, Day 1 .  For patients enrolled in an y Expansion cohorts, Screening cancer evaluations must be performed within 28 days of 
Cycle 1, Day 1.    
9. Hematology will include m easurement of hemoglobin, hematocrit, platelets, RBC, reticulocytes , and  WBC with differential.  To shorten the 
duration of the Cycle 1, Day 1 visit, if needed, the safety laboratory blood samples required for this visit may be drawn up to 3 days before Da y 1 
(Cycle 1 only).   
10. Clinical chemistry will include measurement of potassium, sodium,  chloride, glucose, BUN, creatinine, creatinine clearance, ALT, AST,  ALP,  
GGT, alkaline phosphatase, indirect bilirubin, direct bilirubin, total bilirubin, total protein, albumin, calcium,  bicarbonate,  magnesium, phosphate , 
lipase, and amylase .  To shorten the duration of the Cycle 1, Day 1 visit, if needed, the safety laboratory blood samples required fo r this visit may 
be drawn up to 3 days before Day 1 . 
11. Thyroid panel will include TSH, free T4, and free and total T3  and will be repeated on D1 of each cycle .  
12. Coagulation tests will include PT and aPTT  and will be repeated on D1 of each cycle .  
13. Urinalysis will include color, turbidity, pH, specific gravity, glucose, ketones, nitrites, bilirubin, urobilirubin, protein, RBCs, WBCs , epithelial cells, 
casts, cryst als, and bacteria, and eGFR at Screening only . 
14. A full physical examination will be conducted at Scr eening and at Follow -up.  At each other study visit, patients will be assessed for continued 
dosing and any possible physical symptoms/toxicities and a physical examination may be performed , if indicated .  Body weight should be measured 
at each study visit .  Height should be measured at Screening.  
15. Ophthalmology evaluations will be conducted at least on Day 1 and at Follow -up by a qualified ophthalmologist and will include visual acuity, 
pupil exam, confrontation visual field, extraocular motility and alignment , interior slit lamp examination, and dilated fundus examination of the 
retina .  Additional ophthalmology evaluations may be performed  at any other time, if indicated,  as determined by the investigator.  
16. Vital signs will be measured before any blood draws scheduled for the same time point.  Vital signs will include blood pressu re, respiratory rate, 
pulse, oxygen saturation, and temperature.  On Days 1 and 5, vital signs  will be measured at pre -dose and at 6 -hour intervals post-dose.  
17. At Screening, 12 -lead ECGs will be performed in triplicate, with each measurement separated by 2 minutes.  The average of the 3 screening ECGs  
will be used to calculate QTc  interval  to deter mine study eligibility.  Thereafter, single 12 -lead ECGs will be performed for all patients prior to drug 
administration on Days 1  and 5 of Cycle 1; on Day 1 of each subsequent treatment cycle; and at the Final Study visit.   
18. Cycle 1 :  Starting o n Day 1 of  Cycle 1, digital Holter monitoring will be performed from 45 minutes pre-dose through 24 hours post -dose.  ECG 
extractions of the continuous Holter recordings will be performed at 45, 30, and 15 minutes pre -dose and at specific post-dose time points 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
CONFIDENTIAL   Page  17 coinc iding with the serial blood sampling time points for pharmacokinetics.  Patients will be instructed to assume a supine positi on 5-10 minutes 
prior to each serial blood sampling time point and remain supine throughout the 5 -minute ECG extraction period just prior to serial blood sample 
collection.  During the 24 -hour Holter monitoring period, a 12 -lead ECG tracing may be printed out at any time while the patient is in the clinic at 
the discretion of the investigator .  If for any reason Holter moni toring is not performed in conjunction with the PK sampling on Day 1  or the 
tracings are of poor quality , Holter monitoring may be performed in conjunction with the PK sampling on Day 5. 
19. Cycle 1:   Serial, 3-mL blood samples will be taken for determination of plasma CPX -POM and metabolites concentrations during Cycle 1  at 0.25, 
0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, and 24.0 hours following completion of the 10 -minute IV infusion on Day 1 an d on Day 5.  Each 
PK sample should be collected as close as possible to the planned time.  The 12.0 hour collection can have a +/ - 1-hour window (collect within 11 to 
13 hours) and the exact time must be recorded.  The actual date and time of each blood sam ple collection will be  accurately  recorded.  
20. Cycle 1:   Complete 24 -hour u rine samples for determination  of CPX -POM and metabolites  concentrations,  and measurement of urine volume will 
be obtained from each patient in urine collection and storage containers  during Cycle 1 .  A sample will be taken at pre -dose on Day  1, and complete 
urine samples will be collected at 0 -12 and 12-24 hour collection intervals post-dose on Days 1 and 5.  The 12 hour collection can have a +/ - 1-hour 
window (collect withi n 11 to 13 hours) and the exact time must be recorded.  
21. Cycle 1:   Urine β-glucuronidase  activity will be determined in the complete 24 -hour urine samples collected  on Day 1 and Day 5 of Cycle 1.  
22. 7-mL blood samples will be obtained in EDTA -containing blood collection tubes at pre -dose on Day 1  and Day 5 of each treatment cycle , and on 
Day 22 of the last treatment cycle .  Plasma and buffy coat (PBMCs) will be isolated, transferred to storage tubes, and stored frozen . 
23. BSA will be calculat ed by the site personnel using the Dubois method of calculation using screening height and baseline weight measurements.  
BSA is to be recalculated before study drug administration on Day 1 of every other treatment cycle, starting with Cycle 3 and  the pati ent’s study 
drug dose adjusted accordingly . 
24. CPX -POM in fusions  will be administered once every 24 hours as 10 -minute IV infusions on Days 1 -5 of each 21 -day treatment cycle .  After 
completion of Cycle 1 for the first 4 to 6 patients, the SRC will review saf ety, PK, and PD data to determine if any changes to the dosing schedule 
are indicated (e.g., adding an additional 5 days of dosing to each treatment cycle) . 
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  18 GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS  
AE adverse event  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
AST  aspartate aminotransferase  
AUC  area under the concentration -time curve  following a single dose  on Day 1  
AUCss  area under the concentration -time curve over the dosing interval at steady -
state following drug administration on Day 14  
AUC [0-t] area under the concentration -time curve following administration of a 
single dose on Day 1  
AUC [t-∞] area under the concentration -time curve following administration of a 
single dose on Day 1 from the last quantifiable concentration (t) to infinity  
AUC inf  area under th e curve from time zero to extrapolated infinite time [AUC(0 
∞)] following administration of a single dose on Day 1 as the sum of 
AUC[0 -t] + AUC(t -∞) 
BSA  body surface area  
CLr single dose (Day 1) and steady -state (Day 14) renal clearance  
CLs systemic clearance following administration of a single dose  on Day 1  
CLss  systemic clearance at steady -state 
Cmax the maximum observed serum/plasma/PBMC concentration of drug  
Cssmax the maximum observed plasma concentration of drug and metabolites 
obser ved at steady -state over the dosing interval  
CPX  ciclopirox  
CPX -G ciclopirox glucuronide  
CPX -O ciclopirox olamine  
CPX -POM  ciclopirox phosphoryloxymethyl ester  (ciclopirox prodrug ) 
CRF  case report form (s) 
CRO  contract  research organization  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT  dose limiting toxicity  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
ELISA  enzyme -linked immunoassay  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  19 FDA  (United States) Food and Drug Administration  
GCP  Good Clinical Practice  
GFR  glomerular filtration rate  
GGT  gamma glutamyl transferase  
GLP  Good Laboratory Practices  
HNSTD  highest non -serious toxic dose  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Co uncil on Harmo nisation  
IL Interleukin  
IRB institutional review board  
IV intravenous  
LC-MS/MS  liquid chromatography tandem mass spectroscopy  
MedDRA  Medical Dictionary for Regulatory Activities  
MIBC  muscle invasive bladder cancer  
mRNA  messenger RNA  
MTD  maximum tolerated dose  
MUGA  multi -gated acquisition  
n number of subjects  
NCI National Cancer Institute  
NOAEL  no observed adverse effect level  
PBMC  peripheral blood mononuclear cell  
PD pharmacodynamic  
PK pharmacokinetic  
PT prothrombin time  
Q1 first quartile  
Q3 third quartile  
qRT-PCR quantitative real -time polymerase chain reaction  
QTc corrected QT interval  
QTcF  QT interval corrected using Fridericia’s formula  
RECIST  Response Evaluation Criteria for Solid Tumors  
RNA  ribonucleic acid  
RP2D  recommended phase 2 dose  
SAE  serious adverse event  
SOC  system organ class  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  20 SRC  Safety Review Committee  
SUSAR  suspected unexpected serious adverse reaction  
tmax the time (observed time point) of C max 
tssmax the time (observed time point) of C maxss 
t½ apparent  elimination half -life 
ULN  upper limit of the normal range  
US United States  
Vd apparent volume of distribution  
VEGF  vascular endothelial growth factor  
Vss Steady -state volume of distribution  
λ apparent first -order elimination rate constant  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  21 2. INTRODUCTION  
CPX -POM is a prodrug of ciclopirox (CPX).  CPX is a synthetic antifungal agent approved 
for topical dermatologic use in the treatment of a broa d spectrum o f fungal organisms 
(Gupta, 2001 ).  CPX and ciclopirox olamine (CPX -O) are contained in a number of marketed 
topical drug products.  CPX  also exerts antibacterial activity against many Gram -positive and 
Gram -negative bacteria ( Abrams et al, 1991 ).  CPX is a hydroxypyridone that is structurally 
unrelated to other antifungal agents and has a unique and complex mode of action.  CPX is 
thought to act through the chelation of polyvalent metal cations, such as iron and aluminum , 
resulting in the inhibi tion of the metal -dependent enzyme systems (e.g., cytochromes, 
catalase, peroxidase), thus disrupting cellular activities, such as inhibiting degradation of 
peroxides within the fungal cells ( Gupta and Plott, 2004 ) and mitocho ndrial electron 
transport processes and energy production ( Sakurai et al, 1978 ; Gupta et al, 1994 ).  It is also 
thought that CPX affects the cytoplasmic membranes, inhibiting transport of essent ial 
elements in the fungal cell, disrupting the synthesis of DNA, ribonucleic acid ( RNA ), and 
protein ( Gupta  and Plott,  2004 ).  In addition, CPX may have anti -inflammatory activity as 
demonstrated by its ability to inhibit the  synthesis of prostaglandins and leukotri enes in 
human polymorphonuclear  cells ( Abrams  et al,  1991 ) and to inhibit the formation of 5 -
lipoxygenase and ciclo -oxygenase ( Bohn  and Kraemer,  2000 ; Hanel et al,  1991 ).   
CPX has demonstrated in vivo and/or in vitro anticancer activity in a t least 17 types of solid 
tumor and hematologic cancers  (CPX -POM Investigators Brochure, 2017 ).  CPX modulates 
iron-dependent enzymes and signaling pathways resulting in inhibition of cell growth, 
proliferation , and survival.  CPX has been demonstrated to chelate intracellular iron in 
human cancer cells ( Kwong  et al, 2015 ; Eberhard  et al,  2009; Sidarovich  et al,  2015 ), which 
plays an important role in cancer cell death resulting from exposure to CPX ( Clement  et al,  
2002 ; Szüts  and Krude , 2004 ; Eberhard et al, 200 9; Sidarovich et al, 2015 ).  CPX exposure 
altered expression of 54  proteins in stem cells, including those associated with nucleo tide 
binding, biosynthetic processes, gene expression, regulation of transcription, cell cycle 
processes, RNA and messenger RNA ( mRNA ) processing, and embryonic development 
(Dihazi et al, 2011). 
Scientists at the University of Kansas synthesized the phosphoryloxymethyl ester of CPX, 
CPX -POM to enable parenteral administration of CPX.  In contrast to CPX and CPX -O, 
CPX -POM has high water solubility and is readily formulated for parenteral administr ation.   
Pharmacokinetic (PK) studies in laboratory animals showed that CPX -POM  is rapidly and 
completely metabolized to its active metabolite, CPX, which then disappears from plasma 
following systemic administration of CPX -POM.  Following systemic adminis tration of 
CPX -POM, the dose is eliminated from the body via renal clearance of CPX and the inactive 
glucuronide metabolite of CPX (CPX -G).   
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  22 In rats, intravenous (IV) CPX -POM administered for 28 consecutive days did not cause 
mortality or changes in body weight, food consumption, ophthalmology, hematology, 
coagulation, clinical chemistry, urinalysis, or organ weights.  There were no test item -related 
findings grossly or microscopically at the highest dose level tested (50 mg/kg/day).  Test 
item-related tra nsient clinical signs, including slight to moderate decreased activity, increased 
respiration, eating -like behavior, and slight to moderate incoordination were noted 
immediately after dosing at 50 mg/kg/day.  The no observed adverse effect level (NOAEL) 
in rats was 25 mg/kg/day in males and 50 mg/kg/day in females.  
In dogs, CPX -POM administered for 28 consecutive days did not cause mortality or changes 
in body weight, food consumption, electrocardiogram (ECG) parameters, hematology, 
coagulation, clinical c hemistry, urinalysis, or organ weights.  There were no test item -related 
findings grossly or microscopically at dose levels up to 30 mg/kg/day.  Test item -related 
transient clinical signs such as salivation, fecal changes, aggression, shaking, and tremors 
were noted after dosing at the highest dose level tested on the study (30 mg/kg/day).  
Convulsion was apparent in one dog on a single occasion.  Test-item related ophthalmic 
changes were noted in 3/10 dogs treated with 30 mg/kg/day.  Thus, the NOAEL in dog s was 
determined to be 10 mg/kg/day and the highest non -serious toxic dose (HNSTD) in the dog 
was determined to be 30 mg/kg.   
The starting dose of CPX -POM in patients  was selected b ased on the results of the IV CPX -
POM 28 -day Good Laboratory Practices (GL P) toxicology studies conducted in the rat and 
dog and consistent with FDA guidance ( FDA, 20 10) (see Section 4.4).   
CicloMed is aware of 2 published report s of CPX -O administered orally to humans ( Minden 
et al, 2014 ; Kellner et al, 1981 ).  Following oral administration of CPX -O to patients with 
refractory hematologic malignancies, evidence of pharmacodynamic  (PD) activity was 
observed  (Minden et al, 2014 ; Song et al, 2011 ).  Administrat ion by the oral route of 
administration, however, is not feasible because of dose -limiting gastrointestinal toxicity and 
poor oral bioavailability  due to high first pass effect  (Minden et al, 2014 ).   
The Investigator’s Broch ure provides further details of the nonclinical studies and published 
clinical evaluations of CPX -POM ( CPX -POM Investigator’s Brochure, 2017 ).  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  23 3. OBJECTIVES  
The primary objective of this study is:  
• To evaluate the dose limiting toxicities ( DLT s) and maximum tolerated dose 
(MTD ) of CPX -POM administered IV and establish the CPX -POM dose 
recommended for further investigation . 
The secondary objectives of this study are:  
• To characterize the plasma and urine PK of CPX -POM and its metab olites 
following single and multiple dose administration;  
• To identify  preliminary anti-tumor activity of CPX -POM;  
• To determine urine β -glucuronidase activity in patients participating in the trial.  
The exploratory objective s of this study are: 
• To charact erize the pharmacologic effects of CPX -POM on circulating biomarkers of 
Wnt and Notch cell signaling pathways;  
• To explore PD relationships between changes in circulating biomarkers and drug 
and/or metabolites exposure and other outcomes.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  24 4. STUDY DESIGN  
4.1. Overa ll Design  
This is a first -in-human, Phase 1, multicenter, open label, dose escalati on study to evaluate 
the DLT s and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX -POM 
administered IV in patients with any histologically - or cytologically -confirmed s olid tumor 
type.  Secondary objectives include characterization of the safety and PK profile of 
CPX -POM and identification of preliminary anti -tumor activity in this patient population.  
Biomarkers and their relationship to PK and other outcomes will be examined as an 
exploratory objective . 
The study will initially employ an accelerated titration  design, with a single patient enrolled 
in each cohort (i.e., Single -Patient Cohorts).  The initial patient cohort will receive 
CPX -POM at a starting dose of 30 mg/m2.  Doses will be escalated in 100% increments (i.e., 
doubling), until  a ≥Grade 2 toxicity (with the exception of alopecia), as determined according 
to the United States (US) National Cancer Institute (NCI) Common Terminology Crit eria for 
Adverse Events (CTCAE), version 4.03, is encountered, at which point that cohort and all 
subsequent cohorts will follow a classical “3 + 3” dose  escalation design (i.e., standard 
cohorts).   
After each cohort is completed, a Safety Review Committe e (SRC ) comprised of the CRO 
Medical  Monitor, Principal Investigator (s), and Sponsor representatives will meet to discuss 
the data and decide upon the next dose escalation.  Doses in the standard cohorts will be 
escalated in 25 to 50% increments, based on SRC decision, until the MTD is reached.   In 
addition, after completion of Cycle 1 for the first 4 to 6 patients, the SRC will review safety, 
PK, and PD data to determine if any changes to the dosing schedule are indicated.  
Intrapatient dose escalation will  not be allowed in any patient at any time.  
Each patient in a dose cohort must have received at least 8 0% of their CPX -POM doses, 
unless due to toxicity, during Cycle 1 with follow -up safety evaluations through Day 22 (or 
Cycle 2, Day 1, if continuing in the study) to be eligible for the assessment of DLT.   
Patients may continue to receive cycles of CPX -POM until progress ion of disease , 
intolerable toxicity occurs, or another withdrawal criterion applies.  
Approximately 24 patients will be enrolled in the Single -Patient and Standard Dose 
Escalation Cohorts to establish the MTD.  In addition to these estimated 24 patients, 
Expansion Cohort(s) may be enrolled after the MTD is reached to either explore different 
dosing schedules, increase the experience with a particular tumor type (e.g., muscle invasive 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  25 bladder cancer [MIBC]), or to examine the safety and anti -tumor activity o f CPX -POM in 
combination with certain other anticancer agents.   
All patients  are to attend a Follow -up Visit 28 days (± 5 days) after the last study drug dose.  
No follow -up after completion of the Follow -up Visit is planned, with the exception of 
monitor ing of ongoing treatment -emergent adverse events (AEs) until resolution or until the 
AE is clearly determined to be due to a patient’s stable or chronic condition or intercurrent 
illness(es).  
Dose escalation procedures will be conducted as shown in Table 2. For further details and 
example  doses, see Section 4.2. 
Table 2. Dose Escalation Procedures  
Accelerated Titration (Single -Patient Cohorts; n=1 each)  
No ≥Grade 2 AEs  • Continue evaluation of single -patient dose cohorts.  
• Escalate by 100% to next dose level.  
At least 1 ≥Grade 2 AE not 
meeting the definition of 
DLT  • Expand current and subsequent cohorts to at least 3  patients (see 
Standard Dose Escalation Scheme below).  
1 DLT  • Expand current cohort up to 6 patients or until 2  DLTs are 
encountered (Standard Dose Escalation Scheme below).  
Standard Dose Escalation (Standard Cohorts; n=3  to 6 each)  
No DLT  • Escalate by 25 −50% to next dose level.  
1 DLT in ≤3 patients  • Expand cohort up to 6 patients.  
1 DLT in 6 patients  • Escalate by 25 −50% to next dose level.  
> 1 DLT in ≤  6 patients  • MTD reached; stop dose escalation.   
• Possibly explore intermediate doses for the RP2D.  
 
Abbreviations:  AE = adverse event; DLT = dose limiting toxicity; MTD = maximum tolerated dose; RP2D = 
recommended Phase 2 dose.  
 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  26 A Dose -Limiting Toxicity will be defined as any of the following , if deemed related to study 
drug: 
• Grade 4 thrombocytopenia of any duration  
• Grade 3 thrombocytopenia with significant hemorrhage of any durat ion  
• Grade 4 absolute neutrophil count ( ANC ) greater than 5 days  
• Febrile neutropenia  
• Grade ≥3 non -hematologic toxicity of any duration, except :  
o Grade 3 nausea, vomiting, or diarrhea and Grade 4 vomiting or diarrhea in the 
absence of maximal medi cal therapy that resolves in 72  hours  
o Grade 3 fatigue lasting <5 days  
o Grade 3 hypertension  that can be controlled with medical therapy  
o An increase of indirect (unconjugated) bilirubin indicative of 
M. Meulengracht/Gilbert’s syndrome  
o Serum lipase and/or serum amylase CTCAE Grade 3 ≤7 consecutive days 
without clinical signs or symptoms of pancreatitis  
• Delay in study drug due to toxicity for >2 weeks   
• alanine aminotransferase ( ALT )/aspartate aminotransferase ( AST ) >3x the upper limit 
of normal ( ULN ) with biliru bin >2xULN without another explanation (e.g., 
cholestasis)  
• Any patient who is unable to receive 80% of the expected dose s of CPX -POM (i.e., 
patients who are unable to receive at least 4 of the 5 scheduled doses) in Cycle 1 
because of AEs will be considere d to have a DLT.  
4.2. Planned Doses for Dose Escalation  
As described in Sections 4.1, 4.4, and 6.1.4 , the starting dose for th is study will be 30  mg/m2 
as a 10 -minute IV infusion once daily for 5 days, repeated every 21 days.  As stated  in 
Section 4.1, the study will initially adopt an accelerated titration design until ≥ Grade 2 
toxicity is encountered.  Therefore , as an example, if the first ≥Grade 2 toxicity is not seen 
before the 120 mg/m2 dose lev el in the early cohorts , then  the doses shown in Table  3 may be 
administered.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  27 Table  3. Example Doses for Accelerated Titration Cohorts  
Cohort  Daily Dose (mg/m2) Number of Patients  
1 30* 1 
2 60 1 
3 120 1 
X Until ≥ Grade 2 toxicity  
* In the unlikely event of a DLT at this low dose, up to 5 more patients would be accrued at this dose.  If >1 
DLT was experienced at this dose, a LOWER dose of 15 mg/m2 would be explored in a further cohort.  
Once ≥ Grade 2 toxicity is encountered , the standard dose escalation scheme (“3 + 3”) will 
apply and dose escalations will proceed in 25 to 50% increments , although these increments 
may be modified by discussion with the SRC, according to toxicity or other data accrued in 
preceding cohorts.  If, for example, the first ≥Grade 2 toxicity occurs at the 240 mg/m2 dose 
level, the doses shown in Table  4 may be administered.  These  doses are EXAMPLES and 
not absolu tes until all data from patients in preceding cohorts have been discussed with the 
Principal Investigators  and the SRC.  Dose increments generally will be smaller as the MTD 
is thought to be approaching.  
Table  4. Example Doses for Standard Dose Escalation Cohorts  
Cohort  Daily Dose (mg/m2) Dose Increase  Number of Patients  
4 240  3 - 6 
5 350  46% 3 - 6 
6 475 36% 3 - 6 
X ? 600  26% 3 - 6 
 
All SRC  discussions and decisions will be documented and patient safety will be the 
paramount concern . 
4.3. Rationale for Study Design  
The primary objective of this study is to determine the MTD of CPX -POM in cancer patients 
with advanced solid tumors .  This informati on will be used to inform the selection of the 
CPX -POM dose to be used in future  studies.   
The proposed study design approach is  to use a single patient accelerated dose escalation 
until Grade ≥2 toxicity is observed, followed by a conventional 3+3 design in order to 
determine the MTD.  In view of prior human clinical experience with systemic exposure to 
CPX, the use of an accelera ted, single patient dose escalation scheme in order to minimize 
patient exposure to suboptimal doses of CPX -POM  is warranted.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  28 4.4. Dose Selection  
Food and Drug Administration guidelines ( FDA, 2010 ) were employed to determine the 
starting dose for this study, 30  mg/m2.  As described in this guidance, a common approach 
for determining a starting dose for small molecule drugs is to use one -tenth the severely toxic 
dose in 10% of the animals (STD10) in rodents OR one -sixth the highest  non-severely toxic 
dose (HNSTD) in non -rodents.  In GLP toxicology studies in rats, the CPX -POM STD10 was 
not reached, so the  highest dose tested (50 mg/kg) was used to determine a safe human 
starting dose of 30 mg/m2  (one-tenth  the STD10 based on mg/m2).  In GLP toxicology 
studies in dogs, the CPX -POM HNSTD was 10 mg/kg based on tremors and convulsion 
observed at 30 mg/kg.  One -sixth of the HNSTD observed in dogs, converted to mg/m2, also 
supports a starting dose of 30  mg/m2 in patients .  
4.5. End of Study De finition  
A patient is considered to have completed the study if he/she has completed the first cycle of 
the study.   
The end of the study is defined as the date of the last procedure for the last patient  in the 
study.   At the end of the study the patient w ill complete the D22 visit as well as the Follow -
Up Visit.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  29 5. STUDY POPULATION  
5.1. Inclusion Criteria  
Patient s must meet all of the following inclusion criteria to be eligible for participation in this 
study.  
1. Patient has histologically - or cytologically - confirme d metastatic or advanced -stage 
solid malignant tumor that is refractory to standard therapy .  Patients should only be 
included if  no therapy exists  or if they have received all standard therapies that would 
be potentially  curative or might provide signific ant benefit.  
2. Patient may have received up to 4 prior lines of cytotoxic chemotherapy or 
immunotherapy for their metastatic disease (e.g., docetaxel + doxorubicin ± 
cyclophosphamide), and also may have received additional prior endocrine therapy, 
as approp riate (e.g., for breast or prostate cancer), or non -myelosuppressive therapy 
(e.g., bevacizumab, trastuzumab).  
3. Patient has experienced progressive disease during or following or was intolerant of 
their most recent treatment regimen.  Supporting information  about prior progressive 
disease will be collected, if available.  
4. Patient is male or female aged ≥18 years.  
5. Patient provided signed and dated informed consent prior to initiation of any study 
procedures.  
6. Patient has an Eastern Cooperative Oncology Group (E COG) performance status of 0 
(fully active, able to carry out all pre -disease activities without restriction) or 1 
(unable to perform physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature) . 
7. Patient has a predicted life expectancy of ≥3 months.  
8. Patient has adequate renal function (creatinine ≤1.5 × ULN) or a GFR of ≥50 
mL/min).  
9. Patient has adequate hepatic function, as evidenced by a total bilirubin ≤1.5 × ULN, 
AST, and /or ALT ≤3 × ULN or ≤5  ×ULN, if due t o liver involvement by tumor.  
10. Patient has adequate bone marrow function, as evidenced by hemoglobin ≥9.0 g/dL in 
the absence of transfusion within the previous 72 hours, platelet count 
≥100×109cells/L, and ANC ≥1.5×109 cells/L.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  30 11. Patient has no significant i schemic heart disease or myocardial infarction within 6 
months before the first dose of CPX -POM and currently has adequate cardiac 
function, as evidenced by a left ventricular ejection fraction of >50% as assessed by 
multi -gated acquisition (MUGA) or ultra sound/echocardiography (ECHO); and 
corrected QT interval (QTc) <470 msec by Fridericia (QTcF).  The eligibility of 
patients with ventricular pacemakers for whom the QT interval may not be accurately 
measurable will be determined on a case -by-case basis by the Sponsor in consultation 
with the Medical Monitor.  
12. Patient and his/her partner agree to use adequate contraception after providing written 
informed consent through 3 months after the last dose of CPX -POM, as follows:  
a. For women:  Negative pregnancy test during Screening and at Day 1  of each 
treatment cycle and compliant with a medically -approved contraceptive 
regimen during and for 3  months after the treatment period or documented to 
be surgically sterile or postmenopausal.  
b. For men:  Compliant with a medi cally -approved contraceptive regimen during 
and for 3 months after the treatment period or documented to be surgically 
sterile.  Men whose sexual partners are of child -bearing potential must agree 
to use 2 methods of contraception prior to study entry, dur ing the study, and 
for 3 months after the treatment period.  
13. Patient is willing and able to participate in the study and comply with all study 
requirements.  
For the expansion cohort (s) of the study ONLY , if needed : 
14. Patient has a specific tumor -type and histology (e.g., locally advanced or metastatic 
bladder cancer ), as designated by the Sponsor based on nonclinical and clinical data 
obtained prior to enrollment in the Expansion Cohort.  
15. Patient has measurable disease,  as determined by the Investigator using the Response 
Evaluation Criteria for Solid Tumors (RECIST), version 1.1  (see Appendix 1). 
5.2. Exclusion Criteria  
Patient s who mee t any of the following exclusion criteria are not to be enrolled in this study.  
1. Patient has a history of risk factors for torsade de pointes (e.g., heart failure, 
hypokalemia, family history of long QT syndrome) or requires the use of concomitant 
medicatio ns that prolong the QT/QTc interval during study participation .  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  31 2. Patient has an abnormal cardiac appearance/heart size, as evidenced by chest X -ray or 
computed tomography (CT) scan.  
3. Patient has an uncontrolled or severe intercurrent medical condition (incl uding 
uncontrolled brain metastases).  Patients with stable brain metastases either treated or 
being treated with a stable dose of steroids/anticonvulsants, with no dose change 
within 4 weeks before the first dose of CPX -POM and no anticipated dose change,  
are allowed.   The decision to exclude a patient from the study for an uncontrolled or 
severe intercurrent medical condition will be made by the Principal Investigator .  
Examples could include epilepsy, resistant infection, or any other neurological 
diseas e that would make clinical assessment difficult . 
4. Patient underwent major surgery within 4 weeks before the first dose of CPX -POM or 
received cancer -directed therapy (chemotherapy, radiotherapy, hormonal therapy, 
biologic or immunotherapy, etc.) or an investigational drug or device within 4 weeks 
(6 weeks for mitomycin C and nitrosoureas) or 5 half -lives of that agent (whichever is 
shorter) before the first dose of CPX -POM.  A minimum of 10 days between 
termination of the investigational drug and admini stration of CPX -POM is required.  
In addition, any drug -related toxicity, with the exception of alopecia, should have 
recovered to ≤Grade 1.  
5. If female, patient is pregnant or breast -feeding.  
6. Patient has evidence of a serious active infection (e.g., infecti on requiring treatment 
with IV antibiotics).  
7. Patient has active Hepatitis A infection.  
8. Patient known human immunode ficiency virus (HIV) or H epatitis B or C infection, as 
such patients may be at increased risk for toxicity due to concomitant treatment and 
disease -related symptoms may preclude accurate assessment of the safety of 
CPX -POM.  
9. Patient has a n important  medical illness or abnormal laboratory finding that, in the 
Investigator’s opinion, would increase the risk of participating in this study.  
10. Patient  is taking warfarin.  
11. Patient has a history of other malignancy treated with curative intent within the 
previous 5 years with the exception of adequately treated non -melanoma skin cancer 
or carcinoma in situ of the cervix. Patients with previous invasive c ancers are eligible 
if the treatment was completed more than 5 years prior to initiating current study 
treatment, and there is no evidence of recurrent disease.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  32 12. Patient has known allergy or hypersensitivity to components of CPX -POM.  
13. Patient is taking any i ron replacement therapy administered IV, IM, or orally due to 
the potential for loss of anticancer activity due to ciclopirox (the active metabolite of 
CPX -POM) chelating iron . 
5.3. Meals and Dietary Considerations  
On Days 1 and 5 of Cycle 1, patients will be r equired to stay at the clinical research unit for 
at least 12  hours for PK sampling and other assessments.  Patients will be encouraged to 
drink eight 8 -oz glasses of water over a 24 -hour period, i.e., 64  oz. total.    
If Day 5 Cycle 1 steady state PK asses sments are postponed to Day 5 of Cycle 2, the 
considerations described above will also be postponed to Day 5 of Cycle 2.   
5.4. Screen Failures  
Patient s who fail inclusion and/or exclusion criteria may not be rescreened for the study.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  33 6. TREATMENTS  
6.1. Investigational Product  
6.1.1.  Description of Investigational Product  
CPX -POM prodrug, sodium ((6 -cyclohexyl -4-methyl -2-oxopyridin -1(2H) -yl) oxy) methyl 
phosphate , is the phosphoryloxymethyl ester of CPX .  CPX -POM will be provided as a 
sterile liquid formulation for IV administration . 
6.1.2.  Packaging and Labeling  
CPX -POM will be packaged in plastic, 10 -mL vials containing CPX -POM 50 mg/mL 
solution.  Vials will be labeled according to applicable regulatory requirements.   
6.1.3.  Storage and Handling  
CPX -POM vials mu st be stored under refrigerated conditions at 2 to 8 ºC.   
Only patients enrolled in the study may receive CPX -POM and only authorized site staff may 
supply or administer CPX -POM.  All CPX -POM must be stored in a secure, environmentally 
controlled, and mon itored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  
6.1.4.  Dosage and Administration  
CPX -POM will be administered as an IV infusion once daily on Days 1 -5 of each 2 1-day 
treatment cycle .  CPX -POM will be added to a 100 mL piggyback bag of 0.9% sodium 
chloride solution and infused  over a 10 -minute period.  The initial dose for the first patient 
enrolled (i.e., Cohort  1) will be 30 mg/m2.   
At baseline, the body surfac e area (BSA) will be calculated by the Dubois method using 
Screening height and baseline weight measurements.  The baseline BSA is to be used to 
determine the patient’s study drug dose.  Thereafter, BSA is to be recalculated on Day 1 of 
every other treatme nt cycle, starting with Cycle 3, and the patient’s study drug dose adjusted 
accordingly.  
Dubois Formula:  BSA= 0.007184 x W0.425 x H0.725 
The dose escalation procedure is described in Section 4, and further details and example  
doses are shown in Section 4.2. 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  34 After completion o f Cycle 1 for the first 4 to 6 patients, the SRC will review safety, PK, and 
PD data to determine if any changes to the dosing schedule are indicated (e.g., adding an 
additional 5 days of dosing to each treatment cycle) . 
6.1.5.  Dose Modifications  
If a patient dev elops  a DLT , CPX -POM dosing should be discontinued  until the toxicity is 
resolved  (see definition of a DLT in Section 4).  If the toxicity resolves to at least Gra de 1, 
treatment may be re -initiated and the dos e of CPX -POM  should be reduced by one dose 
level.  If a patient has a second episode of the same DLT despite dose reduction, they should 
be permanently discontinued from study.   
6.1.6.  Compliance  
Administration of CPX -POM will be performed by site personnel.  Compliance will be 
assessed by inspectio n of drug accountability records at the study site.  
6.1.7.  Accountability  
The investigator or designee (i.e., pharmacist) is responsible for ensuring adequate 
accountability of all used and unused investigational medicinal product, placebos, and 
comparators.   This includes acknowledgment of receipt of each shipment of investigational 
product  (quantity and condition), patient  dispensing records, and returned or destroyed study 
product.   Dispensing records will document quantities received from Cicl oMed and 
quantities administered to patients , including lot number, date dispensed/administered, 
patient  identifier number, and the initials of the person dispensing/administering the 
medication.  
At study initiation, the monitor will evaluate the site’s st andard operating procedure for 
investigational medicinal product disposal/destruction in order to ensure that it complies with 
CicloMed requirements.  Drug may be returned or destroyed on an ongoing basis during the 
study, if appropriate.  At the end of th e study, following final drug inventory reconciliation 
by the monitor, the study site will dispose of and/or destroy all unused investigational 
medicinal product supplies, including empty containers, according to these procedures.  If the 
site cannot meet CicloMed’s requirements for disposal, arrangements will be made between 
the site and CicloMed or its representative for destruction or return of unused investigational 
medicinal product supplies.  
All drug supplies and associated documentation will be perio dically reviewed and verified by 
the study monitor over the course of the study.   
Further guidance and information for the final disposition of unused investigational product  
is provided in the Study Procedures Manual . 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  35 6.2. Prior and Concomitant Medications  
Medications taken within 30 days before baseline (Study Visit 2) must be recorded as prior  
medications.   
Prohibited concomitant medications include any anti-cancer agents, steroids  (except stable 
doses being taken for brain metastases) , any iron  replacement  therapy , warfarin , or any drug 
known to have significant nephro toxicity.  A minimum of 10 days between termination of  the 
prohibited concomitant medications or a duration of five elimination half -lives will be 
required prior to administration of IV CPX -POM to eligible patients.  Radiation therapy is 
also prohibited.   
All concomitant medications will be recorded from the tim e of Screening through the 
Follow -up Period.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  36 7. DISCONTINUATION OF STUDY INTERVENTION AND 
PATIENT  DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
Treatment should be discontinued for a  DLT until the toxicity is resolved.  If treatment is 
reinit iated, then the dose of CPX -POM  should be reduced  as described in Section 6.1.5 .  If a 
patient has a second episode of the same DLT despite dose re duction, he or she  should be 
removed from study  as outlined in Table  1. Schedule of Assessments  (complete D22 and the 
Early Termination Visit) . 
In the event of discontinuation of CPX -POM, every effort should be made to complete the 
assessments that are scheduled for the Follow -up/Early Termination visit .  See the Schedule 
of Assessments ( Table  1) for data to be collected at the time of early termination . 
7.2. Patient  Discontinuation/Withdrawal from the Study  
A patient  may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, 
or administrative reasons.  
If the patient  withdraws consent for disclosure of future information, the Sponsor  may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a patient  withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
If a patient withdraws prematurely from the trial for any reason, stud y staff should make 
every effort to complete the full set of evaluations scheduled for the  Follow -up/Early 
Termination visit . See the Schedule of Assessments ( Table  1) for data to be collected at the 
time of early termination . 
7.3. Lost to Follow Up  
A patient  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and i s unable to be contacted by the study site.  
The following actions must be taken if a patient  fails to return to  the clinic for a required 
study visit:  
• The site must attempt to contact the patient  and reschedule the missed visit as soon as  
possible and counsel the patient  on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the patient  wishes to and/or should continue in the 
study.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  37 • Before a  patient  is deemed los t to follow up, the investigator or designee must make 
every effort to regain contact with the patient  (where possible, 3 telephone calls and, if 
necessary, a certified letter to the patient ’s last known mailing address or local equivalent 
methods).  These contact attempts should be documented in the patient ’s medical record . 
• Should the patient  continue to be unreachable, he/she will be considered to have 
withdrawn from the study .  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  38 8. STUDY ASSESSMENTS  
8.1. Cancer Evaluation  
All patients will undergo a c ancer evaluation to include  determination of staging and 
metastases for screening purposes.  Disease response assessments will be performed for 
patients with measurable disease within 28 days prior to the first dose of CPX -POM and 
repeated before the first study  drug dose (Day 1) of every second cycle (i.e., at approximately 
6-week intervals).  If a patient with measurable  disease discontinues from the study after 
6 weeks and before a disease response assessment is scheduled, an additional assessment 
may be perfo rmed, upon consultation with the Sponsor , at the end of treatment  (i.e., on 
approximately Day 22 of the last cycle) .   
For the screening  assessments, all sites of disease will be imaged by CT , if possible .  If the 
anatomic region cannot be adequately image d by CT, magnetic resonance imaging ( MRI ) 
may be used instead.  Subsequent assessments should use the same radiographic methods as 
used during  Screening .  Disease response will be assessed by the investigator using RECIST, 
version 1.1  (Eisenhauer et al, 20 09; see Appendix 1).  Tumor markers applicable to the 
patient’s solid tumor type (e.g., prostate -specific antigen [PSA] for prostate cancer; cancer 
antigen -125 [CA -125] in ovarian cancer; carcinoembryonic antigen [CEA] in colorectal or 
pancreatic cancer, cancer antigen 19 -9 [CA-19-9] in pancreatic cancer) will also be measured 
within ±2 days of tumor measurements . 
8.2. Safety Assessments  
8.2.1.  Adverse Events and Serious Adverse Events  
8.2.1.1.  Definition s 
Adverse Event  
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
medicinal product and which does not necessarily have a causal relationship with this 
treatment.  An AE can therefore be any unfavorable and unintended sign, symptom, or 
disease temporally associated with the use of a medicinal product, whet her or not considered 
related to the medicinal product.  
AEs also include the following:  
• Pre- or post -treatment complications that occur as a result of protocol mandated 
procedure  (e.g. such as venipuncture, biopsy) during or after Screening (before the 
administration of study investigational medicinal product).  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  39 • Any pre -existing condition that increases in severity, or changes in nature during or as a 
consequence of the study investigational medicinal product phase of a human clinical 
trial, will also be con sidered an AE.  
• Complications and termination of pregnancy (see Section  8.2.2 for additional information)  
• All AEs that occur from the study screening visit onwards and throughout the duration of 
the study, including the follow -up off study medication period should be recorded as an 
AE. 
An AE does not include the following:  
• Medical or surgical procedures (e.g. , surgery, endoscopy,  tooth extract ion, transfusion)  
performed; t he condition that leads to th e procedure is an AE. 
• Pre-existing diseases or conditions or laboratory abnormalities present or detected before  
the screening visit that  do not worsen .  
• If progression of underlying malignancy is clearly consistent with the suspected 
progression of the underlying cancer as defined by RECIST 1.1, or with clinical 
symptoms (clinical progression), it should not be reported as an AE /SAE.  Similarly, 
hospitalization due exclusively to the progression of  underlying malignancy should NOT 
be reported as an SAE . 
• Situations where an untoward medical occurrence has not occurred (e.g. , hospitalization 
for elective surgery, social  and/or convenience admissions) . 
• Any medical condition or clinically significant la boratory abnormality with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not 
an AE.  It is considered to be pre -existing and should be documented on the medical 
history CRF.  
• Uncomplicated pregnancy.  
• An induced elective abortion to terminate a pregnancy without medical reason.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs, symptoms, and/or clinical sequelae  
resulting from lack of efficacy  may be reported as AE or SAE  if they fulfil l the definition 
of an AE or SAE.  
Serious Adverse Event  
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e .g., hospitalization for signs/symptoms of the disease under study, death 
due to progression of disease).  
A SAE  is defined as any untoward medial occurrence that, at any dose:  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  40 • Results in death  
• Is life -threatening.  The term 'life -threatening' in the definition of 'serious' refers to an 
event in which the patient  was at risk of death at the time of the event. It does not refer to 
an event, which hypothetically might have caused death, if it were more severe.  
• Requires inpatient hospitalization or prolongation of e xisting hospitalization.  In general, 
hospitalization signifies that the patient  has been detained (usually involving at least an 
overnight stay) at the hospital or emergency ward for observation and/or treatment that 
would not have been appropriate in the  physician’s office or outpatient setting. 
Complications that occur during hospitalization are AEs. If a complication prolongs 
hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as 
to whether “hospitalization” occur red or was necessary, the AE should be considered 
serious.  Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
• Results in persistent disability/incapacity.  The term disability mean s a substantial 
disruption of a person’s ability to conduct normal life functions.  This definition is not 
intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and a ccidental trauma 
(e.g., sprained ankle) which may interfere with or prevent everyday life functions but do 
not constitute a substantial disruption.  
• Is a congenital anomaly/birth defect in the offspring of a subject who received 
investigational medicinal pr oduct.  
• Other situations.  Medical or scientific judgment should be exercised in deciding whether 
SAE reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospitaliz ation but may 
jeopardize the patient  or may require medical or surgical intervention to prevent one of 
the other outcomes listed in the above definition. These events should usually be 
considered serious.   Examples of important medical  events include invas ive or malignant 
cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.  
8.2.1.2.  Time Period and Frequency for C ollecting A dverse Event and Serious 
Adverse Event  Information  
All AEs and SAEs will be collected from the signing of the informed consent form (ICF) 
through the Follow -up visit.   
Medical occurrences that begin before the start of study intervention but a fter obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions 
section of the CRF  not the AE section.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  41 Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if th e investigator learns of any SAE, including a death, at any time 
after a patient  has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the investigator must 
promptly no tify the Sponsor . 
8.2.1.3.  Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to introduce bias when detecting AE s and/or SAEs . Open -ended and 
non-leading verbal questioning of the patient  is the preferred method to inquire about 
AE occurrence s. 
8.2.1.4.  Regulatory Reporting Requirements for Serious Adverse Event s 
Prompt notification (within 24 hours  from the first time a site team member is made aware of 
the event ) by the investigator to the Sponsor  of a SAE is essential so that legal oblig ations 
and ethical responsibilities towards the safety of patient s and the safety of a study 
intervention under clinical investigation are met.  
The Sponsor  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor  will comply with country -specific regulatory requirements relating to  safety 
reporting to the regulatory authority, Institutional Review Boards (IRB) , and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and Spon sor policy and 
forwarded to investigators as necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information ( e.g., summary or listing of SAEs) from the Sponsor  will review and then 
file it along with the Investigator’s Brochure and will notify the IRB, if appropriate according 
to local requirements.  
8.2.1.5.  Reporting  Procedures  
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation ( e.g., hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event.   The investigator will then record all relevant AE/SAE information in the 
CRF . 
It is not acceptable for the investigator to send photocopies of the patient ’s medic al records in 
lieu of completion of the AE/SAE CRF  page.   There may be instances when copies of 
medical records for certain cases are requested by CicloMed or its designee.  In this case, all 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  42 patient  identifiers, with the exception of the patient  number, w ill be redacted on the copies of 
the medical records before submission.  
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information.  Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
All SAEs will be recorded and reported to the Sponsor  or their designee within 24 hours  from 
the time any  site team member is made aware of the event .  The investigator will submit any 
updated SAE data to th e Sponsor  within 24 hours of it being available.   If any part of the 
source providing details of the event is not available, the Investigator will submit the SAE 
with as much information as he/she has at the time of the reporting requirements.  
Contacts and  procedures for SAE reporting can be found in the Study Procedures Manual.   
8.2.1.6.  Assessment of Causality  
The investigator is obligated to assess the relationship between CPX -POM  and each 
occurrence of each AE/SAE as follows:  
• There is a "reasonable possibility " of a relationship between the CPX -POM and the AE.  
This conveys that there are facts, evidence, and/or arguments to suggest a causal 
relationship, rather than a relationship cannot be ruled out.  
• There is not a “reasonable possibility” of a relationship b etween CPX -POM and the AE.  
The investigator will use clinical judgment to determine the relationship.  Alternative causes, 
such as underlying disease(s), concomitant therapy, and other risk factors, as well as the 
temporal relationship of the event to stud y intervention administration will be considered and 
investigated.  The investigator will also consult the Investigator’s Brochure (IB) in his/her 
assessment.  
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the  AE/SAE and has provided an assessment of causality.  
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor or contract research organization 
(CRO ). However, it is v ery important that the investigator always make an assessment of 
causality for every event before the initial transmission of the SAE data to the Sponsor or 
CRO.  The investigator may change his/her opinion of causality in light of follow -up 
information an d send a SAE follow -up report with the updated causality assessment.  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.   
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  43 The relationship to study procedures (e.g., invasive procedures such as venepuncture  or 
biopsy) should also be assessed using the following considerations:  
• There is a reasonable possibility that t he AE occurred as a result of protocol -mandated 
procedures such as venipun cture or biopsy.  
• There is not a reasonable possibility tha t the AE occurred as a result of a protocol -
mandated procedure.   
8.2.1.7.  Assessment of Intensity  
The investigator will make an assessment of intensity  (Grade)  for each AE and SAE reported 
during the study , using as a guide the NCI CTCAE , as provided in the Study Procedures 
Manual .   
8.2.1.8.  Follow -up of Adverse Events and Serious Adverse Events  
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by CicloMed or its 
design ee to elucidate the nature and/or causality of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.  
If a patient  dies durin g participation in the study or during a recognized follow -up period, the 
investigator will provide CicloMed or its designee with a copy of any post -mortem findings 
including histopathology.   
New or updated information will be recorded in the originally c ompleted CRF . 
The investigator will submit any updated SAE data to the Sponsor  within 24 hours of receipt 
of the information.   Contacts for SAE reporting can be found in the Study Procedures 
Manual.  
8.2.2.  Pregnancy  
Pregnancies in female patient s and female partner s of male patient s will be recorded from  
after the start of study intervention until 30 days  after the last dose.   All pregnancies must be 
followed to conclusion to determine outcomes for both mother and baby.   
While pregnancy itself is not conside red to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE.  A spontaneous 
abortion is always considered to be an SAE and will be reported as such.  Any post -study 
pregnancy -related SAE consid ered reasonably related to the study intervention by the 
investigator will be reported to the Sponsor  as described in Section s 8.2.1.4  and 8.2.1.5 .  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  44 While the investigator is not obligated to actively seek this information in former s tudy 
patient s, he or she may learn of an SAE through spontaneous reporting.  
8.2.2.1.  Male Patients  with Partners who Become Pregna nt 
The investigator will attempt to collect pregnancy information on any male patient ’s female 
partner who becomes pregnant while the male patient  is in this study. This applies only to 
male patient s who receive CPX -POM . 
After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate fo rm and 
submit it to the Sponsor  within 24 hours of learning of the partner’s pregnancy.  The female 
partner will also be followed to determine the outcome of the pregnancy.   Information on the 
status of the mother and child will be forwarded to the Sponsor .  Generally, the follow -up 
will be no longer than 6 to 8 weeks following the estimated delivery date.  Any termination 
of the pregnancy will be reported regardless of fetal status (presence or absence of 
anomalies) or indication for the procedure.  
8.2.2.2.  Female  Patients  who Become Pregnant  
The investigator will collect pregnancy information on any female patient  who becomes 
pregnant while participating in this study.   Information will be recorded on the appropriate 
form and submitted to the Sponsor  within 24 hours of learning of a patient 's pregnancy. The 
patient  will be followed to determine the outcome of the pregnancy.   The investigator will 
collect follow -up inform ation on the patient  and the neonate and the information will be 
forwarded to the Sponsor .  Generally, follow -up will not be required for longer than 6 to 
8 weeks beyond the estimated delivery date.   Any termination of pregnancy will be reported, 
regardles s of fetal status (presence or absence of anomalies) or indication for the procedure.  
Any female patient  who becomes pregnant wh ile participating in the study will discontinue 
CPX -POM and be withdrawn from the study.  
8.2.3.  Other Safety and Screening Assessments  
8.2.3.1.  Cardiac  Evaluation  
Patients will undergo a cardiac evaluation at Screening using MUGA or ECHO to evaluate 
their eligibility to participate in the study.  
Patient s will also undergo a  chest X -ray or CT scan  to confirm normal cardiac 
appearance/heart size  at Screening.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  45 8.2.3.2.  Eastern Cooperative Oncology Group  
Patients will be evaluated for ECOG performance status at Screening  and Follow -Up to 
evaluate their eligibility to participate in the study.  The ECOG performance status grades 
and criteria are shown in Table  5. 
Table  5. Eastern Cooperative Performance Status  
GRADE  ECOG PERFORMANCE STATUS  
0 Fully active, able to carry on all pre-disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities; up 
and about more than 50% of waking hours  
3 Capable of only limited selfcare; confined to bed or chair more than 50% of waking 
hours  
4 Completely disabled; cannot carry on any selfcare; totally confined to bed or  chair  
5 Dead  
*Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology 
Group.  Am J Clin Oncol.  1982 ;5:649 -655. 
 
8.2.3.3.  Physical Examinations  
A complete physical examination will be conducted at Screening and Follow -up.  At each 
other study visit, patients will be assessed for continued dosing and any possible 
symptoms/toxicities and a physical examination may be performed, if indicated  (see 
Schedule of Assessments , [Table  1]).  Body weight should be measured at each study visit .  
Height should be measured at Screening.  
8.2.3.4.  Vital Signs  
Vital signs will include blood pressure, respiratory rate, pulse, oxygen saturatio n, and 
temperature  and will be measured at the times and days shown in the Schedule of 
Assessments (Table  1).   
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  46 Vital signs will be measured before any blood draws or injections scheduled for the same 
time point.   
8.2.3.5.  Electrocardiograms  and Holter Monitoring  
At Screening, 12 -lead ECGs will be performed in triplicate, with each measurement 
separated by 2 minutes.  The average of the 3 screening ECGs will be used to calculat e QTc 
and QTcF (Fridericia’s formula):   
to determine study eligibility.  Thereafter, single 12 -lead ECGs will be performed at the dates 
and times indicated in the Schedule of Assessments ( Table  1).   
On Day  1 of Cycle 1, digital Holter monitoring will be performed from 45 minutes  pre-dose 
through 24 hours post -dose in order to examine an y potential QTc changes and relate those, 
if present, to simultaneously obtained blood samples for plasma drug and/or metabolite 
concentration determination.  ECG extractions of the continuous Holter recordings will be 
performed at 45, 30, and 15 minutes p re-dose and at specific post-dose time points coinciding 
with the serial blood sampling time points for PK.  Patients will be instructed to assume a 
supine position 5  to 10 minutes prior to each serial blood sampling time point and remain 
supine throughout  the 5 -minute ECG extraction period just prior to serial blood sample 
collection.  During the 24 -hour Holter monitoring period, a 12 -lead ECG tracing may be 
printed out at any time while the patient is in the clinic at the discretion of the investigator .   
If for any reason Holter monitoring is not performed in conjunction with the PK sampling on 
Day 1  or the tracings are of poor quality , Holter monitoring may be performed in conjunction 
with the PK sampling on Day 5.   
8.2.3.6.  Clinical Laboratory Assessments  
All protocol -required laboratory assessments, including hematology  (including complete 
blood count ), clinical chemistry  (including  comprehensive metabolic panel) , thyroid panel, 
coagulation testing, and urinalysis must be conducted in accordance with the Study 
Procedures Manual and the Schedule of Assessments (Table  1). 
Abnormal laboratory tests that are clinically s ignificant should also be recorded as AEs on 
the CRF , or as medical history if noted during Screening.  
A listing of clinical laboratory tests to be performed is provided in  Table  6.   

CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  47 Table  6. Listing of Required Screening and Safety Laboratory Parameters  
Laboratory 
Assessments  Parameters  
Hematology  
(CBC with 
differential)  • Hemoglobin  
• Hematocrit  
• Platelet count  
• RBC count  
• Reticulocytes  WBC Count with Differential  
• Neutrophils  
• Lymphocytes  
• Monocytes  
• Eosinophils  
• Basophils  
Clinical 
Chemistry  
(including CMP)  • Potassium  
• Sodium  
• Chloride  
• Glucose  
• BUN  
• Creatinine   
• Creatinine 
clearance  
• ALP  • ALT  
• AST  
• GGT  
• Alkaline 
phosphatase  
• Direct bilirubin  
• Indirect bilirubin  
• Total bilirubi n • Total protein  
• Albumin  
• Calcium  
• Bicarbonate  
• Magnesium  
• Phosphate  
• Lipase  
• Amylase  
Coagulation  • PT • aPTT   
Thyroid Panel  • TSH  • Free T4  • Free and total T3  
Routine 
Urinalysis  • Color  
• Turbidity  
• pH 
• Specific gravity  
• Glucose  
• Ketones  • Nitrites  
• Bilirubin  
• Urobilirubin  
• Protein  
• RBCs  
• WBCs  • Epithelial cells  
• Casts  
• Crystals  
• Bacteria  
• eGFR (Screening 
only)  
Other  • Serum or urine 
hCG pregnancy 
test (for women of 
child bearing 
potential)  • HIV ( Screening  
only) • Hepatitis A 
(Screening only)  
• Hepatitis B 
(Screening only)  
• Hepatitis C 
(Screening  only) 
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; aPTT = activated partial 
thromboplastin time; AST = aspartate aminotransferase; BUN = blood urea nitrogen;  CBC = complete 
blood count; CMP = comprehensive metabolic panel;  eGFR = estimated glomerular filtration rate; 
GGT  = gamma glutamyltransferase; hCG  = human chorionic gonadotropin; MCH  = mean corpuscular 
hemoglobin; MCV = mean corpuscular volume; PT = prothrombin time; RBC = red blood cell; T3 = 
triiodothyronine; T4 = thyroxine; TSH  = thyroid stimulating hormone; WB C = white blood cell.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  48 8.2.3.7.  Ophthalmologic Examinations  
Ophthalmologic examinations will be performed  by a qualified ophthalmologist at Screening 
and Follow -up as indicated in the Schedule of Assessments (Table  1).  Evaluations will 
include visual acuity, pupil exam, confrontation visual field, extraocular motility and 
alignment , interior slit lamp examination, and dilated fundus examination of the re tina.  
Additional ophthalmology evaluations may be requested at any other time, if indicated, as 
determined by the investigator.  
8.3. Pharmacokinetic Assessments  
Serial, 3-mL blood (plasma) samples will be taken for PK analysis of CPX -POM and 
metabolites at the times and days shown in the Schedule of Assessments (Table  1).  Each PK 
sample  should be collected as close as possible to the planned time.  The actual date and time 
of each blood sample collection will be recorded.   PK samples may not be obtained from the 
same site where CPX -POM is infused.  
Urine samples for PK analysis of CPX -POM and metabolites  and measurement of urine 
volume  will be obtained from each patient in urine collection and storage containers.  
Samples will be collected during Cycle 1 only at the times and days shown in the Study 
Procedures Manual and the Schedule of A ssessments (Table  1).  Urine β-glucuronidase  
activity  will be determined in the urine samples collected for PK analysis . 
The actual date and time of each sample collection, and the date and time of the previous 
dose of CPX -POM will be recorded.  Processing, storage , and shipping procedures are 
provided in the Study Procedures Manual . 
8.4. Pharmacodynamic  Assessments  
Serial 7 -mL b lood samples will be collected to characterize the pharmacologic effects of 
CPX -POM on circulating biomarkers of Wnt and Notch cell signaling pathways at the times 
and days shown in the Schedule of Assessments ( Table  1).  Plasma and peripheral blood 
mononuclear cells (PBMCs) will be isolated from blood.   VEGF, IL -6, and IL -8 
concentrations will be measured in plasma by enzyme -linked immunoassay (ELISA).  
Quantitative Real -Time Polymerase Chain Reaction (qRT -PCR) will be used to characterize 
gene expression of circulation biomarkers of Wnt and Notch signal ing pathways in PBMCs.  
The actual date and time of each sample collection and the date and time of the previous dose 
of CPX -POM will be recorded.  Processing, storage, and shipping procedures are provided in 
the Study Procedures Manual.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  49 9. STATISTICAL CONSIDE RATIONS  
The statistical analysis plan will be developed and finalized before database lock and will 
describe the finalized plans for analysis of study data .  This section is a summary of the 
planned statistical analyses  at the time of protocol development . 
9.1. Number of Patient s 
The maximum anticipated number of patients in the Single Patient and Standard Dose 
Escalation Cohorts will be approximately 24.   In addition to these estimated 24 patients, 
Expansion Cohort(s) may also be enrolled after the MTD is reached.  
The actual nu mber of patient s enrolled will depend on the nu mber of  dose escalations and the 
need to further characterize individual cohorts.    
9.2. Analysis Sets 
9.2.1.  Safety  
The Safety  Set will con sist of  all patient s who receive at least 1 dose of study drug.   All 
safety and PD data will be analyzed using the safe ty set.  
9.2.2.  Pharmacokinetics  
The Pharmacokinetic  Set will con sist of  all patient s for whom  a plasma  and/or urine sample 
is obtained and analyzed  for determination of p lasma drug and metabolites concentration . 
9.3. Data Handling Conventions  
9.4. Demographic  Data and Baseline Characteristics  
Demographic and baseline measurements will be su mmarized using standard descriptive 
methods.  
9.5. Safety Analysis  
Safety data will be presented in by -patient listings.  Categorical safety endpoints will be 
summarized by frequency of events/abnormalities for each dose group and overall.  
Continuous safety endpoints will be summarized using descriptive statistics (n, mean, 
standard deviati on, median, Q1, Q3, minimum, maximum) for each dose group and overall.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  50 9.5.1.  Determination of Maximum Tolerated Dose  
The MTD is defined as the highest dose at which 1 or fewer of up to 6 patient s experience a 
DLT.  The MTD will be exceeded if 2 or more patient s in a cohort of up to 6 patient s 
experience a DLT.   The number and proportion of patients who experience a DLT or Grade 2 
or higher AE will be listed and summarized by dose group.  A logistic regression will be used 
to estimate the predicted toxicity probab ility at each dose level.  Details will be provided in 
the statistical analysis plan.   
9.5.2.  Extent of Exposure  
Patient s’ extent of plasma and urine exposure to CPX -POM and metabolites will be 
summarized by dose group.   
9.5.3.  Adverse Events  
Clinical and laboratory AEs will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA). System Organ Class (SOC), High -Level Group Term (HLGT), High -
Level Term (HLT), Preferred Term , and Lower -Level Term (LLT) will be attached to the 
clinical database.  
AEs will be summarized on the basis of  the date of onset for the event.   A treatment -
emergent AE will be defined as any AE that begin s on or after the date of first dose of CPX -
POM.  
Summaries (number and percentage of patient s) of treatment -emergent AEs (by SOC, and 
Preferred Term ) will be provided by dose group and overall : 
9.5.4.  Laboratory Evaluations  
Summaries of clinical laboratory data will be provided using descriptive statistics.   No 
inferential statistics will be provided.   Quanti tative values and change from baseline in 
quantitative values will be summarized by dose group.   Listings of all laboratory results and 
reference ranges will be provided.   
Graded laboratory abnormalities will be defined using the grading scheme based on C TCAE  
(4.03).  The i ncidence  of treatment -emergent laboratory abnormalities, defined as values that 
increase at least one toxicity grade from baseline at any time post baseline up to and 
including the date of last dose of study drug, will be summarized by t reatment group.   If 
baseline data are missing, then any graded abnormality (i.e., at least a Grade 1) will be 
considered treatment emergent.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  51 9.5.5.  Other Safety Evaluations  
Physical examination, ECG  (including Holter Monitor) , ophthalmologic examination, and 
vital signs data will be summarized by dose group and overall.  Concomitant medications 
will be coded using the World Health Organization Drug Dictionary and listed by dose 
group.   
9.6. Pharmacokinetic Analysis  
9.6.1.  Pharmacokinetics in Plasma  
Plasma concentrations of  CPX -POM  and its metabolites will be de termined by GLP -
validated liquid chromatography tandem mass spectroscopy( LC-MS/MS ) assays.  A nalysis 
of resultant plasma CPX -POM ( and its metabolites ) concentration -time data  will be 
performed using  non-parametric PK data analysis methods using Phoenix WinNonlin 7.0  
(Certara LP, Princeton, NJ) .  PK parameters will be listed and summarized for each analyte 
using descriptive statistics (e.g., sample size, arithmetic mean, %  coefficient of variation, 
standard deviation, median, minimum, and maximum).  The following PK parameters will be 
determined:   
• Cmax - Maximum observed plasma concentration (Cmax) observed following 
administration of a single dose  on Day  1 
• Tmax - Time to reach maximum observed plasma concentration (Cmax) 
• AUC [0-t] - Area under the concentration -time curve following administration of a single 
dose on Day  1 
• AUC [t-∞] - Area under the concentration -time cur ve following administration of a sing le 
dose on Day  1 from the last quantifiable concentration (t) to infinity.  
• AUC inf - Area under the curve from time zero to extrapolated infinite time [AUC (0-∞)] 
following administration of a single dose on Day 1 as the sum of AUC [0-t] + AUC (t-∞) 
• Cssmax- Maximum observed plasma concentration at steady -state on Day 5 
• Tssmax - Time to reach maximum observed plasma concentration (Cssmax) on Day 5 
• AUC SS - Area under the concentration -time curve over the dosing interval at steady -state 
following drug administ ration on Day 5 
• λ - Apparent first-order  elimination rate constant  
• t½ - Apparent elimination half -life 
• Cls – Systemic clearance following administration of a single dose on Day 1  
• Clss – Systemic clearance at steady -state 
• Vd – Apparent volume of distributio n 
• Vss – Steady -state volume of distribution  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  52 • Cmax Derived Accumulation Ratio - Cssmax/Cmax 
• AUC Derived Accumulation Ratio - AUC ss/AUC (0 - ∞) 
• CL r – Single dose (Day 1) and steady -state (Day 5) renal clearance   
Plasma drug and metabolite  concentration -time data  and derived plasma PK parameters will 
be presented in tabular and graphic format.  
9.6.2.  Pharmacokinetics in Urine  
Urine  concentrations of CPX -POM  and its metabolites  will be determined by GLP -validated 
LC-MS/MS assays.  Urine PK parameters will be generated using non -parametric PK data 
analysis methods, listed , and summarized for each analyte  using descriptive statistics ( e.g., 
sample size, arithmetic mean, %  coefficient of variation, standard deviation, median, 
minimum , and maxi mum).  The following PK parameters will be determined:   
• Mass excreted  
• Excretion rate  
• Cumulative mass excreted  
Urine β –glucuronidase activity will be measured for each patient and summarized.  
9.6.3.  Covariates and Pharmacokinetics  
The influence of dose, single versus multiple dose administration, β -glucuronidase activity, 
and other potential covariates (e.g., creatinine clearance, concomitant medications, 
concurrent disease) on CPX -POM and metabolite exposure will be examined in an 
exploratory fashion given the limited sample size.  
9.7. Pharmacodynamic Analyses  
The pharmacologic effects of CPX -POM on circulating Wnt and Notch cell signaling 
biomarkers will be characterized.  Plasma concentrations of VEGF, IL -6, and IL -8 will be 
determined prior to, during, and following CPX -POM treatment for each cycle by ELISA.  
Expression of survivin; Notch receptors 1, 2 , and 3; Notch ligand  Jagged -1, Notch target 
proteins HES1, Hey1, cyclin D1, and cMyc; as well as ϒ -Secretase proteins Presinilin -1 and 
Nicastrin, will be determined in PBMCs by qRT -PCR.   
Relationships between observed biomarker changes and drug and/or metabolite exposure as 
well as other measures  will be explored  using descriptive statistics, and/or additional PK/PD 
modeling to support the dose selection for future studies.   Demographic and baseline 
characteristics may  be included in the modeling analysis.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  53 9.8. Interim Analyses  
No formal interim analysis is planned.  After each cohort is completed,  an SRC  comprised of 
the CRO Medical  Monitor, Principal Investigator (s), and  Sponsor representatives will meet 
to discuss the data and decide upon the next dose escalation.  In addition,  after completion of 
Cycle 1 for the first 4  to 6 patients, the SRC will review safety, PK, and PD data to determine 
if any changes to the dosing schedule are indicated.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  54 10. REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS  
10.1. Regulatory and Ethical Con siderations  
10.1.1.  Institutional Review Board/Ethics Committee  
IRBs must be constituted according to the applicable state and federal requirements of each 
participating location including International Council on Harmonisation ( ICH) Good Clinical 
Practice ( GCP ). 
It is the responsibility of each investigational site to submit the protocol, IB, patient  ICF, 
patient  recruitment materials (if applicable), and other documentation as required by the IRB 
to their IRB for review and approval.  A copy of the written approv al must be provided to the 
sponsor  or CRO .  The documentation should clearly mention the approval/favorable opinion 
of the protocol, the patient  ICF, and patient  recruitment materials (if applicable) , including 
respective version dates.  The written approv al and a list of the voting members, their titles or 
occupations , and their institutional affiliations must be obtained from the IRB(s) and 
provided to the sponsor  or CRO  prior to the release of clinical study supplies to the 
investigational site and comme ncement of the study.  If any member of the IRB has direct 
participation in this trial, written notification regarding his or her abstinence from voting 
must also be obtained.  
Sites must adhere to all requirements stipulated by their respective IRB.  This includes 
notification to the IRB regarding: protocol amendments, updates to the patient  informed 
consent, recruitment materials intended for viewing by patient s, IND safety reports, serious 
and unexpected AEs, reports and updates regarding the ongoing revi ew of the trial at 
intervals specified by the respective IRB, and submission of final study reports and 
summaries to IRB.  
It is the responsibility of each investigational site to submit information to the appropriate 
IRB for annual review and annual re -approval.  
10.1.2.  Ethical Conduct of the Study  
This study will be conducted according to the protocol, Code of Federal Regulations (21 
CFR Parts 50, 54, 56, and 312), the Declaration of Helsinki, and ICH GCP.  Each 
investigator will conduct the trial according to applicable loc al or regional regulatory 
requirements.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  55 10.1.3.  Informed Consent  
Prior to any study procedures being performed, patient s and the person conducting the 
consent discussion will be required to sign and date the IRB -approved ICF, and each patient  
will be given a copy.  In addition, this information should be recorded in the patient ’s 
medical record (i.e., source document).  
The written consent document will embody the elements of informed consent as described in 
the Declaration of Helsinki, the Code of Federal Regulations (21 CFR Part  50.25), the ICH 
GCP  guidelines , and in accordance with any local regulations.  The investigator is 
responsible for the preparation, content, and IRB approval of the informed consent.  The ICF 
must be approved by the si te-designated IRB and be acceptable to the sponsor  or CRO . 
The ICF must be written in a language fully comprehensible to the prospective patient .  The 
investigator or designee shall give the patient  adequate opportunity to read the ICF  before it 
is signed and dated.  Information should be given in both oral and written form whenever 
possible and in the manner deemed appropriate by the IRB.  Patient s must be given ample 
opportunity to inquire about details of the study.  
10.1.4.  Confidentiality  
The investigator must assure that patient s’ anonymity will be strictly maintained and that 
their identities are protected from unauthorized parties.  
Patient s will be assigned a unique identifier by the sponsor.  Any patient  records or datasets 
that are transferred to the sponsor will contain the identifier only; patient  names or any 
information which would make the patient  identifiable will not be transferred.  
NOTE :  The investigator must keep a screening log showing codes,  names, and addresses  for 
all patient s screened and for all patient s enrolled in the trial.  
The patient  must be informed that his/her personal study -related data will be used by the 
sponsor in accordance with local data protection law.  The level of disclo sure must also be 
explained to the patient .  
The patient  must be informed that his/her medical records may be examined by clinical 
quality assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB members, and by inspect ors from regulatory authorities.  
The investigator agrees that all information received from CicloMed, including but not 
limited to the Investigator Brochure, this protocol, CRF s, the investigational new drug, and 
any other study information, remain the sol e and exclusive property of CicloMed during the 
conduct of the study and thereafter.  This information is not to be disclosed to any third party 
(except employees or agents directly involved in the conduct of the study or as required by 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  56 law) without prior written consent from CicloMed.  The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by any employee or agent of the study site to 
any third party or otherwise into the public domain.  
10.2. Study Oversight  
10.2.1.  Data Quality Ass urance  
All patient  data relating to the study will be recorded in a printed or electronic CRF  unless 
transmitted to the sponsor  or designee electronically ( e.g., laboratory data).   The investigator 
is responsible for verifying that data entries are accurat e and correct by physically or 
electronically signing the CRF .  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF .  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections  and provid e direct access to source data documents.  
The sponsor  or designee is responsible for the data management of this study including 
quality checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF  by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of patients are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
10.2.2.  Source Documents  
Source documents provide evidence for the existence of the patient  and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
Data reported on the CRF  that are transcribed from source documents must be consistent 
with the source documents or th e discrepancies must be explained.   The investigator may 
need to request previous medical records or transfer records, depending on the study . Also, 
current medical records must be available.  
Definition s of what constitutes source data can be found in the Study Procedures Manual . 
10.2.3.  Study and Site Closure  
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed on a 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  57 rolling basis upon data base lock for each site individually or as the Sponsor determines .  A 
study site is considered closed when all required documents , study supplies , and 
investigational product have been collected and/or destroyed, a nd a study -site closure visit 
has been per formed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may  include but 
are not limited to:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of patient s by the investigator  
• Discontinuation of further CPX -POM  development  
10.2.4.  Reporting of Results  and Publications  
CicloMed will  fulfill its commitment to publicly disclose the results of this study  through 
posting the results on  the www.clinicaltrials.gov  web site .   
A clinical study report will be prepared and provided to the regulatory agency(ies).  
CicloMed  will ensure that the report meets the standards set out in the ICH Guideline for 
Structure and Content of Clinical Study Repo rts (ICH  E3). Note that an abbreviated report 
may be prepared in certain cases . 
Any investigator will submit any proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30  days before submission of t he 
publication or presentation. The investigator will comply with CicloMed ’s request to delete 
references to its confidential information (other than the study results) in any paper or 
presentation and agrees to withhold publication or presentation for an additional 60  days in 
order to obtain patent protection if deemed necessary.  
The results of this study may be published or presented at scientific meetings.  If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor  before 
submission. This allows the sponsor to protect proprietary information and to provide 
comments.   
The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor  will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In this 
case, a coordinating investigator will be designated by mutual agreement.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  58 Authorship will be determined by mutual agreement and in li ne with International Committee 
of Medical Journal Editors authorship requirements.  
10.2.5.  Study Files and Retention of Records  
The investigator must maintain adequate and accurate records to enable the conduct of the 
study to be fully documented and the study da ta to be subsequently verified. These 
documents should be classified into at least the following two categories:  (1) investigator’s 
study file, and (2)  patient  clinical source documents.  
The investigator’s study file will contain the protocol/amendments, CRF and query forms, 
IRB, and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and 
correspondence.  
The required source data includes  at least the follo wing information for each patient : 
• patient  identification (name, date of birth, gender);  
• documentation that patient  meets eligibility criteria, i.e., history, physical examination, 
and confirmation of diagnosis (to support inclusion and exclusion criteria);  
• participation in trial (including trial number);  
• trial discussed and date of informed consent;  
• dates of all visit s; 
• documentation that protocol specific procedures were performed;  
• results of efficacy parameters, as required by the protocol;  
• start and end date (including dose regimen) of trial medication;  
• record of all AEs and other safety parameters (start and end da te, and preferably 
including causality and intensity);  
• concomitant medication (including start and end date, dose if relevant; dose changes 
should be motivated);  
• date of trial completion and reason for early discontinuation, if applicable.  
All clinical study documents must be retained by the investigator until at least 2  years after 
the last approval of a marketing application in an ICH region (i.e., United States, Europe, or 
Japan) and until there are no pending or contemplated marketing ap plications in an ICH 
region; or, if no application is filed or if the application is not approved for such indication, 
until 2  years after the investigation is discontinued and regulatory authorities have been 
notified. Investigators may be required to ret ain documents longer if required by applicable 
regulatory requirements, by local regulations, or by an agreement with CicloMed . The 
investigator must notify CicloMed before destroying any clinical study records.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  59 Should the investigator wish to assign the s tudy records to another party or move them to 
another location, CicloMed  must be notified in advance  (i.e. in the case of a Principal 
Investigator moving to a new location, retiring, etc.).  If a study site is assigned to another 
investigator for archival oversight or if the files are to be moved, this change will be noted in 
a memo, the Sponsor will be contacted, and the IRB will be notified depending on the IRB 
requirements.  
If the investigator cannot guarantee this archiving requirement at the study site  for any or all 
of the documents, special arrangements must be ma de between the investigator and  
CicloMed  to store these in sealed containers outside of the site so that they can be returned 
sealed to the investigator in case of a regulatory audit.   When s ource documents are required 
for the continued care of the patient , appropriate copies should be made for storage outside of 
the site.  
Biological samples at the conclusion of this study may be retained in storage by the sponsor  
for a period up to  2 years f or purposes of this study.  
10.2.6.  Case Report Forms  
For each patient  enrolled, a  CRF  must be completed and signed by the Principal Investigator 
or sub -investigator (as appropriate) within a reasonable time period after data collection.   
This also applies to recor ds for those patient s who fail to complete the study (even  during a 
screening period if a CRF  was initiated).   If a patient  withdraws from the study, the reason 
must be noted on the CRF .  If a patient  is withdrawn from the study because of a treatment -
limiting AE, thorough efforts should be made to clearly document the outcome.  
10.2.7.  Inspections  
The investigator should understand that source documents for this trial should be made 
available to appropriately qualified personnel from CicloMed  or its representatives , to IRBs , 
or to regulatory authority or health authority inspectors.  
10.2.8.  Protocol Compliance  
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.  
10.2.9.  Study Discontinuatio n 
Both the sponsor and the investigator reserve the right to terminate the study at any time. 
Should this be necessary, both parties will arrange discontinuation procedures and notify the 
appropriate regulatory authority(ies)  and IRBs.   In terminating the study, CicloMed  and the 
investigator will assure that adequate consideration is given to the protection of the patient s’ 
interests.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  60 11. REFERENCES  
Abrams  BB, Hanel H. Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. 
Clin Dermatol . 1991; 9(4):471 -477. 
Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% 
in the treatment of onychomyosis. J Am Acad Dermatol . 2000 ;43(4):S57 -S69. 
Clement PMJ, Hanauske -Abel HM, Wolff EC, Kleinman HK, Park MH. The antifungal drug 
ciclopirox inhibits deoxyhpusine and proline hydroxylation, endothelial cell growth and 
angiogenesis in vitro. Int J Cancer . 2002;100:491 -498.  
ClinicalT rials.gov web site. Available at: https://clinicaltrials.gov/ . Accessed May 18, 2017.  
CPX -POM Investigator’s Brochure. CicloMed LLC . 2017.  
Dihazi H, Dihazi GH, Jahn O, Meyer S, Nolte J, Asif AR, Mueller GA, Engel W. 
Multipotent adult germline stem cells a nd embryonic stem cells functional proteomics 
revealed an important role of eukaryotic initiation factor 5A (Eif5a) in stem cell 
differentiation. J Proteome Res . 2011;10:1962 -1973.  
Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R,  Datti 
A, Batey RA, Wrana J, Antholine WE, Dick JE, Schimmer AD . Chelation of intracellular 
iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and 
myeloma cells . Blood . 2009;114(14):3064 -3073. 
Eisenhauer EA, Therasse P, Bogaer ts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck 
S, Gwyther S, Mooney M, Rubinstein L, Shakar L, Dodd L, Kaplan R, Lacombe D, Verweij 
J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
Eur J Cancer . 2009;45 :228-247.  
[FDA ] Food and Drug Administration. Guidance for Industry  – S9 Nonclinical Evaluation 
for Anticancer Pharmaceuticals. March 2010. Available at: 
https://www.fda.gov/downloads/Drugs/Guidances/ucm085389.pdf . Accessed September 18, 
2017.  
Gupta AK . Ciclopirox: an overview. Int J Dermatol . 2001; 40(5):305 -310. 
Gupta AK, Plott T. Ciclopirox: a broad -spectrum antifungal with antibacterial and anti -
inflamm atory properties. Int J Dermatol . 2004 ; 43(Suppl 1):3 -8.  
Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part 1. J Am Acad 
Dermatol . 1994;30(5 Pt 1):677 -698. 
Hanel  H, Smith -Kurtz E, Pastowsky S. Therapy of seborrheic eczema with an antifungal 
agent with an antiphlogistic effect. Mycoses . 1991; 34(Suppl 1 ):91-93. 
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  61 Kellner HM, Arnold C, Christ OE, Eckert HG, Herok J, Hornke I, Rupp W. Investigations on 
the pharmacokinet ics and biotransformation of the antimycotic ciclopiroxolamine in animals 
and humans after t opical and systemic application. Anzneim -Forsch/Drug Res.  1981 ; 31(II) . 
No. 8a:1337 -1353.  
Kwong W -L, Lok C -N, Tse C -W, Wong E L -M, Che C -M. Anti-cancer iron(ii) co mplexes of 
pentadentate n -donor ligands: cytotoxicity, transcriptomics analyses, and mechanisms of 
action . Chem Eur  J. 2015 ;21:3062 –3072. 
Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase 1 cancer clinical trials. 
JNCI . 2009;101(10):708 -720.  
Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, 
Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K,  Chang H, 
Brandwein JM, Gupta V, Schuh AC, Trudel S, Yee KW, Reed GA, Schimmer AD . Oral 
ciclopirox olamine displays biological activity in a phase 1 study in patients with advanced 
hematologic malignancies. Am J Hematol . 2014 ; 89(4):363 -368.  
Oken M, Creec h R, Tormey D, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group.  Am J Clin 
Oncol.  1982;5:649 -655. 
Sakurai K, Sakeguchi T , Yamaguchi H, Iwata K. Mode of action of 6 -cyclohexyl -1-hydroxy -
4-methyl -2(1H) -pyridone ethanolamine salt (Hoe296). Chemotherapy .1978; 24(2):68 -76. 
Sidarovich V, Adami V, Gatto P, Greco V , Tebaldi T , Tonini GP, Quattrone A . Translational 
downregulation of hsp90 expression by iron chelators in neuroblastoma cells . Mol 
Phar macol.  2015;87(3):513 -524. 
Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, 
Gronda M, Isaac M, Joseph B, Subramanian R, Aman A, Chan A, Hogge DE, Weir SJ, 
Kaspar J, Schimmer AD, Al -awar R, Wrana JL, Altisano L . WNT inhib itor screen reveals 
iron dependence of β -catenin signaling in cancers. Cancer Res . 2011 ;71:7628 -7639.  
Szüts D, Krude T . Cell cycle arrest at the initiation step of human chromosomal DNA 
replication causes DNA damage . J Cell Sci.  2004;117(Pt 21):4897 -4908.  
CicloMed LLC    Clinical Protocol  
CPX -POM    CPX -POM -001, Amendment 4, Version 5.0  
 
 
CONFIDENTIAL   Page  62 12. APPENDIX  
Appendix 1. RECIST Criteria Guidance  
Time Point Response of Measurable Disease (Target Lesions) with or without  
Non-Measurable Disease (Non -Target Lesions)  
Target Lesion Response  Non-Target  
Lesion Response  New Lesions  Overall Response  
CR 
 CR No CR 
CR Non-CR/Non -PD No PR 
CR NE No PR 
PR Non-PD or NE  No PR 
SD Non-PD or NE  No SD 
NE Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
Abbreviations:  CR = Complete Response, PR = Partial Response, SD = Stable Disease, PD = Progressive 
Disease, and NE = Not All Evaluated  
 
 
Time Poin t Response of Non-Measurable Disease  Only  (Non -Target Lesions)  
Non-Target Lesion Response  New Lesions  Overall Response  
CR No CR 
Non-CR/Non -PD No Non-CR/Con -PD 
NE No NE 
Unequivocal Progression  Yes or No  PD 
Any Yes PD 
Abbreviations:  CR = Complete Response, PD  = Progressive Disease, NE  = Not All Evaluated  
Note:  Non-CR/Non -PD is preferred over “Stable Disease” for non-target disease since SD is increasingly 
used as endpoint for assessment of efficacy in some trials , so to assign this category when no lesions can be 
measured is not advised  
 
Note :  If a CR is truly met at a time point, then any disease seen at a subs equent time point, even disease 
meeting PR criteria relative to baseline, makes the disease PD at that time point since disease must have 
reappeared after CR.  
 
Source:  Eisenhauer et al, 2009  
 